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RESUMO 
 
Introdução: O vírus de Epstein-Barr (EBV) tem sido associado com o desenvolvimento de 
tumores epiteliais, tais como carcinoma da nasofaringe (NPC) e, mais recentemente, com o 
carcinoma gástrico (GC). TP53 é um gene supressor tumoral frequentemente mutado em 
tumores humanos; no entanto, em neoplasias malignas epiteliais associadas ao EBV as 
mutações neste gene são raras apesar de ocorrer frequentemente desregulação da via de 
sinalização da p53. Neste estudo, o nosso objetivo foi caracterizar a acumulação de p53 e a 
expressão de TP53 mRNA em tecidos de NPC e carcinoma gástrico associada ao EBV 
(EBVaGC). 
Metodologia: Um estudo retrospetivo foi realizado com 10 NPC, 12 EBVaGC e 31 GC EBV-
negativo (EBVnGC) para avaliar a acumulação e expressão de p53. Foram utilizadas secções 
histológicas a partir de blocos de tecido embebidos em parafina e fixados em formalina (FFPE). 
A deteção de acumulação de p53 foi realizada por imunohistoquimica (IHC) e a expressão do 
mRNA do gene TP53 foi avaliada por qRT-PCR com o GAPDH como mRNA normalizador. 
Resultados: IHC demonstrou que a p53 está acumulada em 42/43 GC e nos 10 casos 
NPC, com mais de 50% dos casos com 50-100% de células com acumulação de p53. Esta 
elevada taxa de acumulação de p53 foi mais comum nos NPC e EBVaGC do que nos 
EBVnGC. Os nossos resultados demonstraram uma diferença estatisticamente significativa na 
acumulação de p53 entre EBVaGC e EBVnGC (p=0,027). Em relação à expressão de TP53, 
nos NPC foi observada a presença de mRNA TP53. Além disso, nos GC a análise da 
expressão do gene TP53 revelou que o nível de TP53 mRNA nos casos EBVaGC foi 
aproximadamente 80% mais baixo (2-ΔΔCt=0,21; p=0,010), quando comparado com EBVnGC, 
e este resultado foi independente dos subtipos histológicos. 
Conclusão: Os nossos resultados demostraram que a acumulação de p53 foi observada 
em 100% das neoplasias epiteliais associadas ao EBV (NPC e EBVaGC) e em 96,8% dos 
EBVnGC. Além disso, nossos dados mostraram uma diferença significativa na acumulação de 
p53 em EBVaGC comparando com EBVnGC, sugerindo que a acumulação de p53 nos 
carcinomas gástrico é dependente de infeção EBV. A diminuição significativa de TP53 mRNA 
nos EBVaGC em comparação com EBVnGC sugere que a carcinogénese viral interfere com 
a via da p53 e que esta parece ocorrer independentemente da presença de mutações.  
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ABSTRACT 
 
Background: Epstein-Barr virus (EBV) has been associated with the development of 
epithelial tumors such as Nasopharyngeal Carcinoma (NPC) and more recently to Gastric 
Carcinoma (GC). TP53 is a tumor suppressor gene frequently mutated in human cancers; 
nevertheless, in EBV-associated epithelial malignancies mutations are uncommon even with 
frequent deregulation of the p53 pathway. In this study, we aimed to characterize p53 
accumulation and TP53 mRNA expression in NPC and EBV-associated gastric carcinoma 
(EBVaGC) tissues. 
Methods: A retrospective study was performed with 10 NPC, 12 EBVaGC and 31 EBV-
negative GC (EBVnGC) cases, in order to evaluate p53 accumulation and TP53 mRNA 
expression. Histological sections of each sample were obtained from formalin-fixed paraffin-
embedded (FFPE) tissue blocks. The detection of p53 accumulation was performed by 
immunohistochemistry (IHC) and TP53 mRNA expression was evaluated by qRT-PCR with 
GAPDH as normalizer mRNA. 
Results: IHC showed that p53 is accumulated in 42/43 GC and all 10 NPC cases, with more 
than 50% of cases showing 50-100% of cells with p53 accumulation. This high rate of p53 
accumulation was more common in NPC and EBVaGC rather than EBVnGC. We found a 
statistically significant difference in p53 accumulation between EBVaGC and EBVnGC 
(p=0.027). Regarding the expression of TP53, in NPC it was observed the presence of TP53 
mRNA. Furthermore, in GC the TP53 expression analysis revealed that the levels of TP53 
mRNA in EBVaGC are almost 80% lower (2-ΔΔCt=0.21; p=0.010) when compared with EBVnGC, 
and these results were independent of the histological subtypes. 
Conclusion: Our results showed that p53 accumulation was observed in 100% of EBV- 
associated epithelial malignancies (NPC and EBVaGC) and in 96.8% of EBVnGC. 
Furthermore, our data demonstrated a significant difference of p53 accumulation in EBVaGC 
comparing with EBVnGC, suggesting that accumulation of p53 in gastric cancer is dependent 
of EBV infection. The significant decrease of TP53 mRNA in EBVaGC comparing with 
EBVnGC, suggests that viral carcinogenesis interferes with the p53 pathway and that this 
seems to occur independently of the presence of mutations.
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ABREVIATIONS LIST 
 
B 
BARTs - BamHI A rightward transcripts 
BER - base excision repair 
BL - Burkitt’s Lymphoma 
BMI - body mass index 
BSCC - basaloid squamous cell carcinoma 
 
C 
CD - cluster of differentation 
CDKs - cyclin-dependent kinases 
cDNA - complementary DNA 
CIMP - CpG island methylator phenotype 
CSF - colony stimulating factor 
 
D 
DAB - diaminobenzidina 
DDB - DNA damage-binding protein 
DNA - deoxyribonucleic acid 
 
E 
EBER-ISH - EBER in situ hybridization 
EBERs - Epstein-Barr Virus-encoded RNAs 
EBNAs - Epstein Barr Nuclear Antigens 
EBV - Epstein-Barr virus 
EBVaGC - EBV associated gastric carcinoma 
EBVnGC - EBV non-associated gastric carcinoma 
 
F 
FFPE - formalin-fixed paraffin-embedded 
 
 
G 
GC - gastric carcinoma  
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H 
HCMC - human cytomegalovirus 
HDGC - hereditary diffuse gastric cancer 
HHV - human herpesvirus 
HSV - herpes simplex virus 
HL - Hodgkin lymphoma 
HLA - human leukocyte antigen  
 
I 
IARC - International Agency for Research on Cancer 
IHC - immunohistochemistry 
IL - interleukin 
IM - infectious mononucleosis 
 
K 
KSCC - keratinizing squamous cell carcinoma 
KSHV - Kaposi’s sarcoma-associated herpesvirus 
 
L 
LOH - loss of heterozygosity 
 
M 
MHC - major histocompatibility complex 
miRNAs - microRNAs 
miRs - also know miRNAs 
MMR - DNA mismatch repair 
mRNA - messenger RNA 
 
N 
ncRNAs - noncoding RNAs 
NER - nucleotide excision repair 
NPC - nasopharyngeal carcinoma 
 
O 
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ORFs - open reading frames 
 
P 
PBS - phosphate-buffered saline 
PBS-T - phosphate-buffered saline containing 0.02% Tween 20 
PCR - polymerase chain reaction 
PTLDs - post-transplantation lymphoproliferative disorders 
 
Q 
qPCR - quantitative polymerase chain reaction 
 
R 
RNA - ribonucleic acid 
ROS - reactive oxygen species 
RT - reverse transcription  
 
S 
SPSS - statistical package for social sciences 
 
T 
TGCA - The Cancer Genome Atlas 
 
U 
USP7 - ubiquitin-specific-processing protease 7 
UV - ultraviolet  
 
V 
VC - variation coefficient  
VCA - viral capsid antigen 
VZV - varicella zoster virus 
W 
WHO - World Health Organization 
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1. EPSTEIN-BARR VIRUS 
 
1.1HISTORICAL BACKGROUND  
The first step towards Epstein-Barr virus (EBV) discovery happened when, in 1958, Denis 
Burkitt described a geographically restricted tumor occurring among children in Tropical Africa, 
later named as Burkitt's lymphoma (BL) [1]. Due to the dependence on temperature and 
humidity of this type of tumor, Burkitt raised the possibility that this was vector-transmitted and 
may be virus-induced [2]. Burkitt's hypothesis was clarified in 1964, when Anthony Epstein, 
Yvonne Barr and Bert Achong, using electron microscopy, discovered herpesvirus-like particles 
in the “Epstein-Barr” cell line derived from a BL biopsy. The virus was then named Epstein-Barr 
Virus (EBV) [3]. Further studies established this virus as a new member of the human 
herpesvirus family, although antigenically and biologically different from any of the human 
herpesviruses known until then [4, 5].  
In the late 60s, antibodies against EBV were identified in sera of patients with Burkitt's 
lymphoma as well as in healthy individuals [6] and in patients with infectious mononucleosis 
(IM) [7]. Since then, serological studies developed to examine the EBV seropositivity in different 
cancers revealed that the prevalence of EBV antibodies in patients with primary 
nasopharyngeal carcinoma (NPC) was higher when compared to the EBV seropositivity found 
in patients with BL, which increased the interest for the study of NPC [8]. In 1970, zur Hausen 
and his collaborators showed the presence of EBV in NPC and BL cells by in situ hybridization 
and EBV was recognized as the first virus to be directly associated with human cancers [9]. 
 
1.2EPIDEMIOLOGY  
EBV is an ubiquitous pathogen that is harbored by approximately 90% of all adults 
throughout the world [10]. EBV infection, despite easily spread through saliva and 
oropharyngeal secretions, is not highly contagious. In infants, saliva on toys and fingers are the 
main routes of EBV transmission, while in adolescents and adults it is transmitted mainly by 
kissing [11]. 
There are two peaks of seroconversion described by literature, one at 1–6 years and the 
other at 14–20 years [12]. In developing countries, almost all infections occur at an earlier age, 
with more than 90% of children over the age of 2 years being seropositive. Typically, this 
seroconversion occurs at a subclinical level, being asymptomatic or associated with nonspecific 
illness such as low-grade fever or sore throat [13]. In contrast, the developed countries 
commonly have an increased rate of primary EBV infection at the adolescence or early 
Mariana Malta | MSc Oncology
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adulthood, and this late seroconversion leads to a significant numbers of individuals to become 
ill and in 30% to 50% to the development of IM [10, 11, 14]. 
 
1.3BIOLOGY OF EBV 
 
1.3.1Taxonomy 
EBV, known as human herpesvirus 4 (HHV-4), is a member of the family Herpesviridae, 
subfamily Gammaherpesvirinae, genus Lymphocryptovirus with a structure indistinguishable 
from the others human herpesviruses [12].   
The Human Herpesvirus family can be further divided in three subfamilies based on 
biological properties of the viruses such as growth characteristics and cell tropism [15]. The 
alpha subfamily is constituted by neurotropic viruses that primarily infect mucoephitelial cells 
including herpes simplex virus (HSV) 1 and 2, and varicella zoster virus (VZV) [15]. The viruses 
of the gamma subfamily are EBV and Kaposi’s sarcoma-associated herpesvirus (KSHV), both 
lymphotropic viruses. The beta subfamily is characterized by its ability to establish infection in 
many different types of cells and include human cytomegalovirus (HCMV) and human 
herpesvirus (HHV) 6 and 7.  These eight human herpesvirus have a significant impact among 
pediatric population. 
 
1.3.2Structure, Genome and Strain Variability 
The mature virions of EBV are approximately 150 to 200 nm in diameter and are composed 
by three layers surrounding the viral genome [16]. EBV genome have a linear, doubled-
stranded DNA of ~184 kilobase pairs in length and 100x106 Da of molecular weight [12, 17]. 
Like other members of the herpesvirus family, EBV DNA is surrounded by an icosahedral 
nucleocapsid composed by 162 triangular capsomeres, which is enclosed by a protein 
tegument [12, 18]. The third layer is an irregularly shaped envelope constituted of multiple viral 
glycoproteins that play an important role in cell tropism, host range and receptor recognition 
(Figure 1) [12]. 
Structurally the EBV genome comprises short and long sequence domains (US and UL) 
alternate with internal tandem repeat regions (IRs) that are flanked by terminal repeat 
sequences (TRs) [17, 19]. The EBV genome is linear but as soon as the virion reaches the 
nucleus, after the infection of the cell, it adopts an episomal form which is essential for viral 
genome replication [19]. 
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Literature reveals that there are two types of EBV, type 1 and type 2 [12, 16, 20]. They differ 
at the domains which code for the EBV nuclear antigens (EBNAs) - EBNA2, EBNA3A, 
EBNA3B, and EBNA3C [21, 22]. The two EBV strains are distinguished by their patterns of 
restriction endonuclease digestion and biological differences between the two virus types have 
been reported [16] . In vitro studies showed that they differ in their ability to spontaneously enter 
in lytic cycle as well as different transforming capabilities, with EBV-1 being more efficient at 
immortalizing B lymphocytes when compared to EBV-2 [12, 20, 21, 23].  
Despite the absence of specific geographical restriction, EBV-1 has a predominance of over 
95% in the Western hemisphere and Southeast Asia whereas in some regions EBV-2 is more 
prevalent, including central Africa, Papua New Guinea and Alaska [23, 24]. The association of 
these EBV subtypes with specific diseases development is not yet clarified [12]; however, EBV-
1 appears to predominate in majority of EBV-associated diseases while EBV-2 is principally 
related with immunocompromised patients [12, 25]. 
 
1.3.3Primary Infection and Lytic Replication 
Primary EBV infection occurs in the oropharynx, where the virus infects epithelial cells and 
almost simultaneously resting B-cells in adjacent lymphoid tissue [26]. Literature has shown 
that EBV is also capable of infect other cells, including T-cells and natural killer cells, however 
with a much lower efficiency [20].  
Figure 1. EBV virion structure. 
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The infection of epithelial cells leads to the activation of lytic cycle, wherein replication of the 
virus occurs and the mature virions are released. The infection of resting B-cells usually results 
in a latent infection, characterized by the expression of a few of the nearly one hundred proteins 
coded by EBV genome without viral replication and production of virions [10, 27]. Nevertheless, 
in B lymphocytes, EBV infection leads to two distinct outcomes depending on the stage of the 
B cell: 1) when resting B-cells differentiate into memory B cells, EBV establishes a long-term 
persistency characterized by latency; and 2) when B-cells are activated and differentiated into 
plasmocytes, that are destined to die, EBV activates lytic cycle as a survival strategy [27]. 
Lifelong infection of the human host is a result of the synchrony between these two phases of 
infection, hiding it from the immune system in memory B cells and replicate to produce new 
virions, which have the capability to infect more host cells or other individuals [27]. 
EBV attaches to B cells through the binding with different cell surface receptors: while viral 
envelope gp350 glycoprotein binds to B cell surface molecule CD21, also known as the C3d 
complement receptor [28]; the viral glycoprotein gp42 interacts with the major histocompatibility 
complex (MHC) class II molecule serving as a co-receptor for EBV [29].  In epithelial cells, the 
lack CD21 is compensated by the interaction of EBV BMRF-2 protein with adhesion molecules 
of cell surface, such as the β1 integrins, and afterwards EBV gH/gL envelope protein is able to 
triggers fusion via interaction with αvβ 6/8 integrins [16]. The subsequent steps of endocytosis 
of the virus into vesicles and fusion of the virus with the vesicle membrane leads to the release 
of the nucleocapsid into the cytoplasm. These nucleocapsid is then dissolved and the EBV 
genome is transported from the cytoplasm to nucleus, where replication begins through the 
action of DNA polymerases [16, 20]. Lytic viral replication is accompanied by expression of 
almost 100 viral proteins and viral lytic gene products can be divided in three temporal classes: 
immediate-early (IE), early (E) and late (L) [16, 30]. The major immediate-early proteins of EBV 
are encoded by BZLF1 (also termed Z Epstein–Barr replication activator, ZEBRA, or Zta) and 
BRLF1 (also known as Rta). BZLF1 and BRLF1 are essentials for the switch from latency to 
lytic cycle and their presence is the earliest indicator of lytic infection. These two proteins 
activate transcription of viral early genes [12, 20]. The early genes (also termed early antigens, 
EA) are a group of viral transcripts composed by around 30 early proteins that have a wide 
range of functions that include replication, metabolism, and blockade of antigen processing. 
The early proteins BHRF1 and BALF1 are capable of protect infected cells from apoptosis due 
to their homology with bcl-2, a cellular protein that inhibits apoptosis; BHRF1 also acts as 
colony stimulating factor (CSF)-1 receptor, blocking the ability of CSF-1 to enhance secretion 
of the cytokine, and inhibits cell death in both B-cells and epithelial cells; BALF1 modulate the 
Mariana Malta | MSc Oncology 
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effect of BHRF1 in epithelial cells; and BSMLF1 and BMRF1 proteins, which belong to early 
antigen–diffuse complex, activate expression of other early genes [20]. 
EBV late lytic genes comprise a family of nucleocapsid proteins, viral glycoproteins and a 
viral cytokine. Viral capsid antigen (VCA) is the major nucleocapsid protein and its detection is 
used in the diagnosis of virus infection [12]. EBV glycoproteins include gp350, gp85, gp42, and 
gp25, all involved in viral infectivity and spread. EBV gp350 is the major viral envelope protein 
and when binds to CD21 promotes virus attachment to B cell. The trimolecular complex, formed 
by gp85, gp42, and gp25, is responsible for the virus entry into cells: gp85 is responsible for 
virus fusion with B-cells and virus absorption by epithelial cells; gp25 works as a viral chaperone 
to transport gp85 to the cell membrane; and gp42 binds to MHC class II molecules and act as 
co-receptor for EBV entry in B cells. Nevertheless, gp42 is not necessary for epithelial cells 
infection because this cells do not have MHC class II molecules [12, 20]. The viral cytokine IL-
10, that has 80% similarity with human IL-10 and less activity than its cellular homolog, inhibits 
interferon gamma secretion and release of IL-12, protecting the virus-infected cells from 
cytotoxic T-cells, and stimulates growth of B-cells (Figure 2) [20]. 
 
 
 
 
Figure 2. EBV infection in healthy carriers. 
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1.3.4Latent infection  
As all human herpesvirus, EBV can establish a lifelong latent state of infection, characterized 
by persistent, non-productive viral infection in which the virus genome is maintained in the 
nucleus of the infected cell without production of virions [16, 31] . In latently infected B cells, 
EBV genome normally exist as an episome, although some studies report that, in some cases, 
virus genome can become integrated within host DNA [32]. Despite this, during latent infection, 
EBV genome seems to behave as host chromosomal DNA; it is packaged with cellular histones, 
replicated once in S phase via host DNA polymerase, and divided equally into daughter cells 
during the mitotic phase [16, 30]. 
 
1.3.4.1 Latent Gene Transcripts  
In contrast with lytic replication, there is a limited expression of EBV genes during latency. 
These include six EBV-encoded nuclear antigens (EBNAs) (EBNA1, 2, 3A, 3B, 3C and leader 
protein (EBNA-LP)), three latent membrane proteins (LPMs) (LMP1, 2A and 2B), EBV-encoded 
small RNAs (EBERs) (EBER1 and 2) and BamHI A rightward transcripts (BARTs) [12, 16, 33]. 
Together, EBV latent genes target multiple cellular and signaling pathways, and thus, 
contributing to carcinogenesis in EBV-associated malignancies [34]. 
 
a. EBV-encoded nuclear antigens (EBNAs) 
EBNA1 was the first EBV latent protein to be reported and is expressed in both stages of 
the infection, playing multiple essential roles in latent infection, including replication and mitotic 
segregation of EBV episomes. EBNA1 contributes for the persistence of viral genome in latent 
infection and to cell immortalization throughout its function as transactivator of EBV latent 
genes. EBNA1 is also capable of modify the cellular environment, and thus, contributing to cell 
survival and proliferation as well as viral persistence [33, 35].  
EBNA2 and EBNA-LP are co-expressed shortly after B cell infection and EBNA2 has been 
considered crucial for EBV-mediated B-cell immortalization by contributing for the 
transactivating expression of several other viral genes [36]. EBNA-LP is a specific coactivator 
of EBNA2 and, although not essential for B cells transformation, enhances the immortalization 
of infected B cells by complementing the effect of EBNA2. Together, EBNA2 and EBNA-LP 
activate viral and cellular gene transcription for B cells transformation [33, 36].  
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EBNA3A, EBNA3B and EBNA3C are a family of proteins with a central role in EBV latency 
in B cells by reprogramming host genes expression and, thus, affecting cell proliferation, 
survival, differentiation and immune surveillance [37]. EBNA3A and EBNA3C are classified as 
viral oncoproteins because they target tumor suppressor pathways involved in the proliferation 
of cells and both are essential for B-cell transformation [37, 38]. In contrast, EBNA3B is 
completely dispensable for in vitro B-cell transformation and could be a virus-encoded tumor 
suppressor. EBNA3B, contrary to EBNA3A and EBNA3C, upregulates CXCL10, an T cell–
chemoattractant, and has a growth inhibitory role [33, 37]. Importantly, in B-cell lymphomas 
EBNA3B is frequently mutated and its inactivation promotes immune evasion and virus-driven 
lymphomagenesis [39]. 
 
b. Latent membrane proteins (LMPs) 
LMP1 is expressed in the majority of EBV-associated malignancies and has a high potential 
for the deregulation of cellular signal transduction pathways and as a result, target cell 
proliferation and, simultaneously, subvert cell death programs [40]. LMP1 is also important in 
regulation of tumor angiogenesis through the global alteration of gene and microRNA 
expression patterns. In addition, LMP1 has other functions that include cytokine and chemokine 
induction, immune modulation, cell–cell contact, cell migration, and invasive growth of tumor 
cells [40, 41]. 
LMP2 has two isoforms, LMP2A and LMP2B, which differ in their 5' exons, and is expressed 
in many EBV-associated malignancies [42]. LMP2A mimics cellular signaling pathways of B 
cells, leading these cells to a state of proliferation and activation, which provides a favorable 
environment for viral replication [43]. Besides, LMP2A is also capable of induce ubiquitination-
dependent proteasomal degradation of cellular proteins. These two counterbalancing 
mechanisms of LMP2A allow the virus to stay in a latency state without inducing an effective 
immune response of the host [19, 42]. LMP2B lacks the 19-amino acid N-terminal domain 
present in LMP2A that is responsible for modulation of cellular signal transduction pathways in 
B cells [42]. Indeed, LMP2B function in EBV infection is not yet completely understood; 
however, some studies suggest that it is involved in the regulation of switching from latent to 
lytic state of EBV infection in B cells through the regulation of LMP2A. LMP2B seems to 
negatively regulate the function of LMP2A and might be responsible for the inhibition of 
modification of cellular signaling pathway induced by LMP2A [42, 44, 45]. 
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c. EBV Noncoding RNAs 
EBV expresses a large number of viral noncoding RNAs (ncRNAs) during latent infection, 
including EBV-encoded RNAs (EBERs), BamHI A rightward transcripts (BARTs) and viral 
microRNAs (miRNAs or miRs) [46, 47]. 
EBER1 and EBER2 are the most highly expressed EBV RNAs during the latent stage of the 
infection and are commonly used to detect/identify the presence of EBV in tissues [20]. The 
role of EBERs in EBV-induced B-cell transformation is not yet fully understood. While initial 
studies have postulated that they were dispensable, recent reports suggest that EBERs 
expression increases colony formation and growth, enhances resistance of cells to apoptosis 
and cytokines, including IL-10, IL-9, IGF1 and IL-6, and modulates innate immune response 
[33]. 
BARTs are another class of abundant and stable viral transcripts that are detectable during 
both lytic and latent EBV infection. These viral noncoding RNAs were first identified in NPC 
tissues and subsequently in other EBV-associated malignancies. BARTs encode a number of 
potential open reading frames (ORFs) that include BARF0, RK-BARF0, A73 and RPMS1, and 
despite protein products of these ORFs have not been detected, in vitro studies have suggested 
their potential role in negative regulation of EBNA2 and modulation of kinase signaling [20, 46].  
Viral microRNAs (miRs), recently identified as a form of EBV ncRNA, are small, noncoding 
RNAs with 21-24 nucleotides in length. Until now, 44 mature EBV miRs were described of 
which 4 are derived from the BHRF1 cluster and the BART cluster encodes the remaining 40 
miRs. Intriguingly, BART miRNAs seem to be predominantly expressed in latently infected 
epithelial cells whereas BHRF1 miRNAs appear to have high expression levels in B cells 
undergoing stage III latency [48]. Regarding viral miRs function, the presently available 
information indicates that EBV uses its miRNAs to inhibit the apoptotic response in infected cell 
in order to establish latent infection and interferes in the expression of viral genes to mask the 
infected cell and escape from the immune system. However, the importance of viral miRNAs 
in EBV life cycle and malignant transformation need to be clarified [46, 49]. 
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Together, EBV latent gene transcripts may contribute to tumorigenesis by targeting several 
hallmarks of cancer described by Hanahan and Weinberg [50] (Figure 3). 
 
 
 
 
 
1.3.5Latency Patterns 
Literature described the existence of four different latency programs for EBV: Latency I, II, 
III, and 0 [51, 52]. The latency programs differ in their pattern of expression of latent viral 
transcripts and have been associated with different neoplasias [16] (Table 1): Latency I, 
frequently found in Burkitt's Lymphoma, is characterized by EBNA1 and EBERs expression 
[53]; Latency II has been associated with nasopharyngeal carcinoma and Hodgkin's lymphoma 
and in addition to EBNA1 and EBERs, LMP1, LMP2 are also expressed [16, 54]; the full panel 
of viral latent gene products is expressed in Latency III and is found in immunocompromised 
individuals and during acute infectious mononucleosis [16]; and Latency 0 is characterized by 
no viral genes expression and has been described in quiescent, memory B cells [51, 52]. 
Figure 3. EBV latent genes target cancer hallmarks of epithelial malignancies (Tsao et al. 2015). 
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Interestingly, all latency patterns can occur in B cells and are dependent on the B-cell stage 
[55]. Typically, after infecting naïve B cells EBV enters in type III latency, characterized by the 
expression of all latent viral genes, leading to B cell proliferation and resulting in the 
transformation of naïve B cells in proliferating blasts [19]. Later, as B-cells differentiate into 
latently infected memory B-cell, EBV proteins expression becomes restricted to latency II, with 
less viral proteins being expressed [55]. In memory B-cells the virus enters in latent persistence 
phase characterized by no expression of viral proteins - latency 0 [56]. In this latency 0, the 
host immune system is not capable of detect EBV and the latently infected memory cells 
circulate in the peripheral blood. When memory B cells divides, EBV enters in type I latency, 
with a restrictive expression of latent genes, allowing only the replication of EBV genome 
synchronized with memory B cell replication [55]. This process of latency patterns change 
according to B-cell stage is illustrated in Figure 2. 
 
 
 
Table 1. EBV latency programs. 
 EBNA1 EBNA2 EBNA3 LMP1 LMP2 EBERs 
Latency I + - - - - + 
Latency II + - - + + + 
Latency III + + + + + + 
Latency 0 - - - - - - 
EBNA, Epstein–Barr virus nuclear antigen; LMP, Latent membrane protein; EBERs, Epstein–Barr virus-encoded 
small RNAs. 
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2.EBV-ASSOCIATED MALIGNANCIES  
 
EBV infection has been associated with both benign and malignant disorders [34, 57] and 
can be divided in two groups, those that occur in immunosuppressed individuals versus those 
that occur in immunocompetent individuals [58].  
In immunosuppressed individuals, post-transplantation lymphoproliferative disorders 
(PTLDs) are the main chronic disease that arises from EBV infection, with reactivation occurring 
in about 10% of transplant recipients,[10]. 
EBV has been also associated with some lymphoproliferative disorders in 
immunocompetent individuals, such as Burkitt lymphoma and Hodgkin lymphoma [19].  
Burkitt lymphoma (BL) can be divided in endemic or sporadic variants [59]. Endemic-BL 
occurs frequently in children living in equatorial regions of Africa, Papua and New Guinea and 
over 95% are associated with EBV infection. In contrast, sporadic BL has a weak association 
with EBV (only 15 to 30% of cases are EBV-associated) and occurs in young adults with no 
specific geographic distribution [19, 60].  
Hodgkin lymphoma (HL) has been divided into classical HL, which accounts for about 95% 
of all cases, and nodular lymphocyte predominant HL. EBV infection is associated with about 
40% of classical HL cases [61]. 
In addition to lymphoproliferative disorders, EBV has been linked to epithelial malignancies 
that include nasopharyngeal carcinoma and a subset of gastric cancers [19, 58]. The next two 
chapters will focus mainly in these two EBV-associated epithelial carcinomas. 
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2.1NASOPHARYNGEAL CARCINOMA  
 
2.1.1EPIDEMIOLOGY 
Nasopharyngeal carcinoma (NPC) is considered a rare type of cancer, accounting only for 
0.6% of all cancers [62]. According to Globocan, in 2012 occurred 86.700 new cases and 
approximately 50.800 NPC-related deaths worldwide [63].The incidence and mortality rates of 
this neoplasia differ depending on the economic resources of the countries, with economically 
less developed countries having about 11 times more cases and 14 times more deaths per 
year, when compared to more developed regions (Figure 4) [63, 64]. The highest incidence 
and mortality rates of NPC are registered in South-Eastern Asia, which represents more than 
the double when compared to any other area worldwide [63, 64]. In this region, NPC 2 the sixth 
most common cancer among males [64]. In contrast, in more developed regions, namely in 
America and Europe, the incidence of NPC is considerably lower [65]  Regardless of the 
geographical area, NPC is more frequent in males than females with 2 to 3 times higher 
incidence rates in males than in females (Figure 5)  [64]. 
 
 
 
 
 
Figure 4. Nasopharyngeal carcinoma incidence worldwide, both sexes, all ages (Globocan 2012). 
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2.1.2PATHOLOGY 
NPC has origin in epithelial cells from the nasopharynx surface and presents different 
degrees of differentiation [66]. In the 2005 World Health Organization (WHO) classification, 
NPC is divided into three categories: keratinizing squamous cell carcinoma (KSCC), basaloid 
squamous cell carcinoma (BSCC) and nonkeratinizing carcinoma, which is subdivided into 
differentiated and undifferentiated nonkeratinizing carcinomas [67].  
KSCC types are commonly diagnosed in non-endemic areas, such as USA and Japan [67-
69] and its association with EBV infection varies between populations [70-72]. Basaloid 
squamous cell carcinoma is uncommon in both endemic and non-endemic areas, and there is 
very few data reporting EBV infection in this subtype of NPC [67]. Nonkeratinizing carcinoma 
is the most frequent histological type in endemic regions, representing >85%  of all NPC cases 
[67] and it is invariably associated with EBV infection (~100%) [68].  
 
Figure 5. Nasopharyngeal carcinoma incidence worldwide divided by sexes, all 
ages (Globocan 2012). 
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2.1.3ETIOLOGY AND RISK FACTORS  
NPC carcinogenesis has been associated with several etiological factors, including host 
genetics, environmental exposures and EBV infection [73].  
Several studies reported consistent evidence for association of genetic polymorphisms in 
some genes with NPC development, including immune-related HLA Class I genes [74], DNA 
repair gene RAD51L1 [75] and cell cycle control genes MDM2 [76] and TP53 [77]. However, 
the small size of most studies and the lack of attempts to replicate the experiments have limited 
the progress in understanding the genetics of NPC [78]. In fact, search for genes conferring 
susceptibility for NPC development have focused on the human leukocyte antigen (HLA) genes 
[73]. While some HLA alleles, specially HLA-A2-B46 and HLA-A2-B1, have been associated 
with 2- to 3-fold increased risk of NPC development in Asian populations, others like HLA-A11-
A2 and HLA-A11-B13 seem to represent a decreased risk of 30% to 50% in Caucasians and 
Chinese, respectively [79]. 
Large-scale epidemiological studies have proposed associations between several dietary 
and social practices with an increased risk of nasopharyngeal carcinoma [80, 81]. Salt-
preserved fish consumption, which is a dietary base in the most NPC-endemic populations, 
has been reported with a strong association with risk of NPC development with studies 
revealing a relative risk for NPC development between 1.38 and 7.50 [81]. Other preserved 
foods, including meats, eggs, fruits, and vegetables have also been considered [79, 81]. In 
contrast to preserved foods, frequent intake of fresh fruits and vegetables, particularly during 
childhood, has been associated with 30% to 50% decrease in risk of NPC [81, 82]. Although 
the mechanisms by which fruits and vegetables are a protective factors have not been 
thoroughly investigated, it seems that a diet lacking anti-oxidants could lead to the accumulation 
of reactive oxygen species (ROS), which may overwhelm the antioxidant defense system 
resulting in DNA damages and mutations  [81, 83, 84].  
Cigarette smoking has been consensually established as a risk factor for NPC and studies 
showed a 2- to 6-fold increase in the risk of developing NPC [79, 85] . Studies conducted in 
endemic and non-endemic areas reported a significant association between cigarette smoking 
and KSCC, but with little effect on nonkeratinizing cases [86-88]. Contrarily to salt-preserved 
foods, the patterns of association of tobacco smoking with NPC are dependent on the 
population [79, 81]. In addition, the association between alcohol consumption and NPC 
development is not clearly established and the great majority of studies have shown no 
significant association between alcohol consumption and the risk for NPC development. 
However, a meta-analysis revealed an increase of 33% in risk of NPC when the category of 
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the highest alcohol consumption is compared with the group of minimal alcohol intake [89]. 
Other risk factors as use of herbal products (herbal medicines; teas and soups) and 
occupational exposure to formaldehyde and other chemicals or irritants are reported has having 
some association but results are inconsistent [79, 81]. 
EBV infection has been the most intensively studied etiological agent and the evidences 
strongly implicate this virus as a causative factor for NPC development [90]. However, EBV is 
recognized as a necessary but non-sufficient condition to induce malignant transformation in 
nasopharynx epithelial cells [91]. This is corroborated by the fact that >90% of all adults 
worldwide are EBV seropositive and only a minority develops NPC carcinoma [92]. Hence, the 
literature reinforces that EBV may trigger the cancer development in cells that have been 
affected by other carcinogenic agents [68, 93]. 
 
2.1.4EBV AND NPC  
Infection with EBV has been consistently associated to NPC development by several 
different studies that report elevated anti-EBV antibody titters, free EBV DNA in bloodstream 
at diagnosis and monoclonal proliferation of tumor cells EBV-positive [94]. Indeed, studies have 
shown that, almost all non-keratinizing tumors contain monoclonal EBV genomes [54].  
Although the carcinogenesis mechanism associated to EBV infection in NPC is not fully 
understood, the accumulated evidence suggests that viral infection occurs before clonal 
expansion of malignant cells. EBV genome is detected in NPC tumor cells as well as in high-
grade pre-invasive lesions (severe dysplasia and carcinoma) [95]. Nevertheless, in low-grade 
dysplastic lesions and normal nasopharyngeal epithelium, EBV genome is not detected and 
the most frequent modification found is the loss of heterozygosity (LOH) in both 3p and 9p 
chromosomes [96, 97]. The identification of genetic changes in pre-malignant lesions when 
EBV is not detected in the cells has led to the proposal of a multi-step model for the 
pathogenesis of NPC - Figure 6 [98].  
Allelic losses of chromosomes 3p and 9p, which lead to inactivation of tumor suppressor 
genes, are probably the first step of NPC development and might be the result of exposure to 
environmental carcinogens, such as tobacco and salt-preserved fish [95, 99, 100]. Interestingly, 
chromosomes 3p/9p allelic losses in the normal nasopharyngeal epithelium is much more 
frequent in populations at high risk for NPC development (82.6%) than in the low-risk 
populations (20%) [101]. These findings suggest that  as a result of this genetic changes, low-
grade pre-invasive lesions become susceptible to EBV infection which will then be trigged to 
proliferate leading to NPC development [98, 100]. This hypothesis is supported by in vitro data 
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that showed that EBV infection of epithelial cells requires an altered, undifferentiated cellular 
environment [78].  
As soon as the cells become infected by EBV, the virus express EBERs and the latent 
proteins  LMP1, LMP2 and EBNA1, characteristic of EBV latency II pattern [54]. These EBV 
proteins interact with the host proteins in order to provide mechanisms of growth and survival 
to the cells.  
EBNA1 is expressed in all NPC cells and has an essential role in maintaining the EBV 
genome in the tumors cells [102]. Additionally, EBNA1 also interferes with cellular pathways 
that control cell proliferation, survival, and DNA repair [103]. For example, EBNA1 may protect 
cells from apoptosis through its interaction with p53 binding domain of USP7 and could also 
contribute to the increase of genetic instability in NPC cells through the disruption of 
promyelocytic nuclear bodies, important for DNA repair [104, 105]. 
LMP2A is expressed in more than 98% of all NPC cases, while expression of LMP2B 
appeared lower [106]. LMP2A interferes in different cellular signaling networks, affecting growth 
transformation, differentiation, survival and migration [102]. For example, LMP2A lead to beta-
catenin stabilization, the central oncoprotein of Wnt signaling, inappropriately activating the 
Wnt pathway and thus contributing to survival and growth of malignant cells [107].  
LMP1 is expressed in around 70% of all NPC cases, still its expression varies among 
different studies [108]. Independent of the frequency of expression, a very low level of LMP1 
expression in cells is sufficient to induce growth and apoptosis resistance as well as enhance 
cell motility and invasion [108]. For example, LMP1 upregulates bcl-2, a protein involved in cell 
death regulation, and cooperates with this host protein to induce epithelial cell transformation 
[109]. Furthermore, a recent publication indicates that LMP1 also cooperates with a catalytic 
subunit of the human telomerase to immortalize primary nasopharyngeal epithelial cell cultures 
[110].  
In the last stages of NPC development, LMP1 and LMP2 cooperate to promote aggressive 
growth and invasive properties of cells and additional genetic and epigenetic changes occur, 
ultimately, to confer the tumor cells the ability to metastasize [52, 102]. 
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Figure 6 summarizes the steps towards nasopharyngeal carcinogenesis in which EBV 
infection has an important role in the dysregulation of multiple signaling pathways. 
 
 
 
  
Figure 6. Role of Epstein–Barr virus in the pathogenesis of nasopharyngeal carcinoma (Young et al. 2004) 
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2.2GACTRIC CARCINOMA 
 
2.2.1EPIDEMIOLOGY 
Worldwide, gastric cancer (GC) is the fifth most common diagnosed cancer with an 
estimated 952.000 new cases and approximately 723.000 deaths in 2012, accounting for 6.8% 
of all cancers and being the third leading cause of cancer death in both sexes [63]. In Portugal, 
each year 1834 new cases have been diagnosed with gastric cancer, of which 1387 died from 
the disease, making GC the fifth most common cancer and the fourth most common cause of 
cancer death [63]. 
Incidence rates of gastric cancer are two fold higher in men than in women and vary widely 
across the world (Figure 7 and 8). The highest incidence rates are registered in Eastern Asia 
and Central/Eastern Europe, with almost 60% of all cases occurring in China, Japan and Korea. 
Conversely, Northern America and Africa have the lowest incidence rates [63, 111] (Figure 7). 
Regional variations in gastric carcinoma incidence are, in part, the reflection of differences in 
dietary patterns, salt intake, food storage and prevalence of Helicobacter pylori infection, which 
are the etiological risk factors for GC [64, 111]. 
 
 
 
Figure 7. Gastric carcinoma incidence worldwide, both sexes, all ages (Globocan 2012). 
Mariana Malta | MSc Oncology 
Mechanisms of silencing TP53 in EBV-related neoplasia | 21
 
 
2.2.2PATHOLOGY 
The diagnosis of gastric adenocarcinomas requires histopathologic assessment however, 
tumors of stomach demonstrates marked heterogeneity at both architectural and cytologic level 
that difficult the establishment of a well-defined classification system [112, 113]. Of all stomach 
cancers, around 90% are adenocarcinomas and the remaining 10% are due to Non-Hodgkin’s 
lymphomas and leiomyosarcomas [114].  
Several classification systems have been proposed to describe gastric cancer based on the 
microscopic appearance of tumors, including Ming, Carneiro, Grundmann and Goseki 
classifications [115-118]. Nowadays, Lauren and World Health Organization (WHO) systems 
of classification are commonly used by pathologists (Table 2) [119]. Despite the different 
classification systems describing gastric adenocarcinomas, there is no consensus concerning 
Figure 8. Gastric carcinoma incidence worldwide divided by sexes, all ages 
(Globocan 2012). 
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which is the best system of classification combining prognosis and high practicality in clinical 
diagnosis [119]. 
Since 1965, Lauren's classification has been used to subdivide gastric adenocarcinomas in 
two major categories: intestinal type (or well differentiated) and diffuse type (or 
undifferentiated), plus indeterminate type [120]. These two major subtypes have different 
clinical and pathological characteristics: the diffuse type has equal gender distribution and 
occurs in all age groups, occurs in the corpus or entire stomach and has a greater tendency to 
invade the gastric wall and to metastasize, leading to more rapid disease progression and worst 
prognosis; contrarily, the intestinal type occurs predominantly in males and older persons, 
predominates in the antrum and incisura of the stomach and has better prognosis [114, 121]. 
The 2010 WHO classification subdivides gastric adenocarcinomas in four major groups: 
tubular, papillary, mucinous and poorly cohesive (including signet ring cell carcinoma), plus 
uncommon histologic variants [118]. In this new classification, Lauren's intestinal type is 
branched in tubular and papillary adenocarcinomas and Lauren's diffuse type is divided in 
mucinous adenocarcinoma and poorly cohesive carcinoma [108]. 
 
 
Table 2. Comparison of Lauren’s and WHO classification systems. Adapted from [112]. 
WHO (2010) Lauren (1965) 
Papillary adenocarcinoma 
Intestinal Type 
Tubular adenocarcinoma 
Mucinous adenocarcinoma 
Diffuse Type Signet-ring cell carcinoma 
Poorly cohesive carcinoma 
Mixed carcinoma Indeterminate 
Uncommon variants ------- 
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2.2.3ETIOLOGY AND RISK FACTORS  
Gastric cancer risk factors can be divided in three major groups: infectious agents, 
dietary/lifestyle influences and genetic component [122].  
H. pylori infection affects around 50% of world population and has been classified by WHO 
as a class I carcinogen for the development of non-cardia gastric adenocarcinoma [123]. For 
this subtype of gastric cancer, it is estimated that 89%of all cases are attributable to H. pylori 
infection and that this infection is responsible for a twofold increase in the risk of developing 
GC [121, 124]. The contribution of H. pylori to gastric carcinogenesis is via mechanisms that 
induce chronic gastritis. This chronic gastritis over time may progress to severe atrophic 
gastritis, which in turn can develop to cancer [114]. Although H. pylori infection affects half of 
the world population, only around 0.5% of infected individuals will develop gastric 
adenocarcinoma [125]. Thereby, other risk factors are necessary to stomach carcinogenesis 
as, for example, high-salt intake that could contribute to increase the risk of persistent H. pylori 
infection [126]. 
Nevertheless, recently a second infectious agent has been associated with gastric 
carcinogenesis: the Epstein-Barr Virus [127]. Sousa et al. showed that the worldwide 
prevalence of EBV-positive gastric cancer is 8.29%, with the highest EBVaGC prevalence 
registered in America (11.3%) and the lowest  in Europe (7.96%) [128]. Additionally, Murphy et 
al. demonstrated that this incidence is two times higher in men than in women (11.1% males 
vs. 5.2% females) and regardless of gender, EBV-positive tumors seem to occur more 
frequently in cardia or corpus than in the antrum [129]. The EBV specific mechanism of action 
in gastric carcinogenesis is still unknown, however it is conceivable that EBV infection occurs 
in atrophic gastric cells and leads to carcinoma development [125, 130].  
Dietary and lifestyle risk factors include salt and salted preserved food, fruits and vegetables, 
tobacco, alcohol and body mass index/physical activity [131, 132].  
Dietary intake of salt in excess could result in early atrophic gastritis, thereby increasing the 
later risk of GC. In fact, recent data suggest that high-salt consumption is responsible for a two-
fold increase in the risk of GC development when compared to low-salt intake [122, 133]. 
Conversely, several studies have reported a protective effect of consumption of fresh fruits and 
vegetables, with vitamins C and E, carotenoids and selenium being highlighted as possible 
protective micronutrients. These reports suggest that fruits and vegetables intake contribute to 
a decreased risk of GC in around 20% and 30%, respectively [114, 121].  
The two-lifestyle factors implicated in gastric carcinogens are tobacco smoking and alcohol. 
Like in other types of cancer, tobacco smoking is an unequivocal risk factor for gastric 
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cancer.Smoking was significantly associated with both cardia and non-cardia cancers, being 
responsible for a 1.5-fold increased relative risk of developing GC [121]. In contrast, no definite 
association exists between alcohol and gastric cancer, although some studies have showed a 
slightly increase in risk of gastric cancer associated with alcohol consumption [121, 125].  
Other risk factors, include body mass index (BMI) above 25 reported by a meta-analysis 
showing that overweight and obese population have increased risk to develop non-cardia 
gastric cancer, with an increase in the risk of 1.4-fold for overweight and 2-fold in obese. 
Conversely, regular physical activity seems to be associated with lower risk of non-cardia 
gastric carcinoma [122, 134].  
Inherited predisposition syndromes are associated to around 3% of all gastric cancers. 
These include, for example, hereditary diffuse gastric cancer (HDGC) and Lynch syndrome that 
confer 80% and 10% lifetime risk of developing gastric cancer, respectively [122]. HDGC in a 
rare cancer that is caused by germline mutations in the E-cadherin (CDH1) gene and is 
characterized by autosomal dominance and high penetrance [121]. On the other hand, Lynch 
syndrome is a hereditary predisposition that is genetically heterogeneous, caused by germline 
mutations in various DNA mismatch repair (MMR) genes: MLH1, MSH2, MSH6, or PMS2. 
Lynch syndrome, besides gastric cancer, also predispose to colorectal cancer and endometrial 
adenocarcinomas [135]. 
 
2.2.4EBV AND GASTRIC CANCER 
EBV infection has been detected in almost 10% of all cases of GC and its incidence have 
regional differences [128, 136]. Moreover, the prevalence of EBV-associated gastric cancer 
(EBVaGC) has distinct distribution according to gender and tumor location, being more 
predominant in males and in proximal stomach, such as cardia and fundus [129]. 
Recently, due to the heterogeneity in GC and to the limited clinical utility provided by the 
current systems of classification of gastric tumors, two studies proposed a new classification of 
GC based on molecular features of tumors and categorized EBVaGC as a “new” and distinct 
subtype of GC [137, 138]. EBVaGC seems to exhibit an extreme hypermethylation phenotype, 
also known as EBV-CIMP (CpG island methylator phenotype), with the highest prevalence of 
DNA hypermethylation of all cancers reported by The Cancer Genome Atlas (TGCA) [138]. 
PIK3CA mutations occur in ~80% of EBVaGC, contrasting with the other subtypes wherein 
PIK3CA mutations are not so frequent. EBVaGC has also been described as having mutations 
in ARID1A (55%) and BCOR (23%) genes. Interesting, TP53 mutations that occur in the 
majority of gastric tumors (71%) are rare in EBVaGC. Additionally, the EBV subgroup exhibits 
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amplification at 9p24.1 at the locus containing JAK2 (encodes a receptor tyrosine kinase), 
CD274 (encodes PD-L1) and PDCD1LG2 (encodes PD-L2) [138].  
Taking into account the characteristics of EBVaGC, a recent publication suggests that EBV 
coordinates with somatic gene mutations in order to induce the carcinogenesis process in 
gastric epithelial cells (Figure 9) [139]. In this proposed mechanism, high frequency mutations, 
such as in PIK3CA and ARID1A, are a requirement in the GC development and are responsible 
for the transformation of normal gastric cells into susceptible pre-cancerous cells, which are 
more likely to be infected by EBV. After viral infection and establishment of EBV-latency, other 
lower-frequency mutations, such as BCOR mutation or amplification of PD-L1 and PD-L2, 
might contribute to an increase progression and immune evasion of cancer cells [139]. 
Nevertheless, there is still some lack of information and further studies are necessary to clarify 
the coordination of virus and host cell mutations in gastric cancer carcinogenesis. 
 
 
 
 
 
 
 
 
 
Figure 9. Coordination between EBV and somatic gene mutation in EBVaGC (Abe et al. 2015). 
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3.TP53 
 
3.1 STRUCTURE AND BIOLOGICAL FUNCTIONS 
The human p53 protein is 393 amino acids long and is encoded by TP53 gene, which is 
located on chromosome 17p13.1. This protein has three domains: a transactivation domain, 
which is required for establish contacts with the transcriptional coactivators or co-repressors; a 
sequence-specific DNA binding domain; and a tetramerization domain that regulates the p53 
oligomerization process. [140, 141]. 
The most important function of p53 emerged from the studies in knockout mice that showed 
that these mice deficient in TP53 were susceptible to spontaneous tumorigenesis. Hence, p53 
was recognized as a tumor suppressor protein extremely important in the biological activity of 
cells [142]. Nevertheless, in response to endogenous or exogenous stresses, p53 triggers p53-
regulated responses that include cell cycle arrest, DNA repair, apoptosis and senescence 
(Figure 10). Together these widely studied functions of p53 converge to its main function as 
tumor suppressor in cancer [142]. 
 
 
Figure 10. p53-activating signals and responses important for tumor suppression (Bieging 2014). 
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3.1.1 Cell Cycle Arrest  
Cell cycle arrest is an immediate response to DNA damage that gives cells time to repair 
DNA, and when unsuccessful, the cell can enter apoptosis or the senescence programme 
permanently discontinuing the cell cycle and preventing the organism of the proliferation of 
these cells [143]. p53 interferes with cell cycle progression by several mechanisms that induce 
arrest at the G1/S border (G1 arrest) or the G2/M border (G2 arrest) [144]. Its crucial role in 
induction of G1 arrest occurs trough the induction of transcriptional upregulation of p21, an 
inhibitor of cyclin-dependent kinases (CDKs), which in turn, inhibits the CDK2 that is 
responsible for cell cycle progression from G1 into S-phase [144, 145]. p53 role in  inhibition of 
G2/M progression occurs through the upregulation of several genes (p21, Gadd45A and Btg2) 
and despite the mechanisms are very heterogeneous, it includes interactions with CDK1 and 
regulation of p21 mRNA stability. However, studies have suggested that p53 is not an essential 
piece in the induction of G2 arrest but it appears that p53 and its target genes are required to 
sustain the arrest in G2 [144, 146]. 
 
3.1.2 DNA Repair 
The p53 protein plays a role in DNA repair response to genotoxic stresses by activating both 
nucleotide excision repair (NER) and base excision repair (BER) mechanisms [144]. NER is 
responsible for the removal of bulky DNA adducts, such as UV-induced pyrimidine dimmers 
and polycyclic aromatic hydrocarbon. In NER, p53 promotes the transcriptional activation of its 
downstream effector genes that include Gadd45a (binds to UV-damaged chromatin and 
interacts with core histones and p21) and p48-XPE (the small subunit of the heterodimeric 
damage-specific DNA binding protein (DDB) in the NER protein complex, and as the function 
to bind to UV-damaged DNA) [147]. BER corrects DNA base modifications that are frequently 
induced by reactive oxygen species and endogenous alkylating agents [144]. p53 interacts 
directly with BER proteins enhancing the stability of interaction between DNA polimerase β, 
which performs base excision repair, and DNA abasic sites [148-150]. 
 
3.1.3 Apoptosis  
Apoptosis is the most studied biological function of p53 and is induced in response to cellular 
stresses, such as DNA damage, hypoxia and aberrant oncogene expression [151]. The 
apoptotic process is a vital part of p53 tumor suppressor function and its activation can occur 
through the intrinsic mitochondrial pathway or through the extrinsic death receptor apoptotic 
program [152, 153]. In the intrinsic mitochondrial pathway, the mitochondria is target by a death 
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stimuli and, consequently, releases apoptogenic proteins that lead to caspase activation and 
apoptosis [152]. p53 is intimately involved in this process through transcription-dependent 
activation of bcl-2, such as PUMA, NOXA and BAX, which will disrupt the integrity of the outer 
mitochondrial membrane and leading to the release of apoptosis signaling factors [154]. p53 
can also promote apoptosis via repression of anti-apoptotic genes, such as survivin, resulting 
in the caspase activation [152, 155]. In the extrinsic death receptor pathway, p53 directly 
activates the transcription of genes encoding death receptors, including APO1/FAS/CD95 and 
KILLER/DR5, which are located at the cellular membrane, recruit adaptor proteins and induce 
caspases activation, ultimately culminating in apoptosis [152, 156]. Although the literature 
pointed p53 protein as a regulator of the extrinsic apoptotic pathway, p53-mediated death 
through this via is not yet fully understood [151]. In fact, cells that die via p53-dependent 
apoptosis generally follow the intrinsic mitochondrial pathway [152]. 
 
3.1.4 Senescence 
In the cellular senescence process, proliferation in damaged or potentially oncogenic cells 
is blocked but these cells are not eliminated from tissues [157]. p53 levels do not seem to raise 
during cellular senescence but the p53 DNA binding activity and its transcriptional activity were 
reported as being increased during senescence [158]. Moreover, p21 protein expression 
increases to its highest levels in senescent cells and these findings suggest that p53 may 
induce the senescent state through the transactivation of p21 expression [159]. Although other 
p53 targets and regulators have been linked to induction of senescence, the underlying 
molecular mechanisms are still poorly understood [157, 159].  
 
3.2TP53 AND HUMAN CANCER 
In cancer development, p53 inactivation occurs through different mechanisms that include 
genetic alterations, inactivation by binding to viral or cellular oncoproteins and sequestration of 
the protein in the cytoplasm. Moreover, somatic TP53 gene mutations occur in almost every 
type of cancer [160]. The frequency in somatic TP53 mutations is highly variable, ranging from 
around 50% in ovarian, colorectal, head and neck and lung cancers to about 5% in sarcoma, 
testicular cancer, malignant melanoma and cervical cancer [161]. In fact, the frequency of TP53 
mutations varies according different factor such as the stage of development of the tumor, for 
example in prostate cancer TP53 mutations occurs in 10 to 20% of the primary tumors but in 
the metastatic stage TP53 mutations are described in around 50% of all cases [162]. Viral and 
bacterial infections strongly modulate TP53 mutation frequency due to its capability of interfere 
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with p53 activity [160]. Different mechanisms that interfere with p53 function have been 
reported in DNA tumor viruses. For example, the papillomavirus E6 protein interacts directly 
with p53 to promote its degradation [163]; the hepatitis B virus X protein inhibits the nuclear 
translocation of p53 [164]; and the adenovirus E1B protein interacts directly with p53 and 
inhibits its acetylation [165]. Thus, the modulation of p53 function is clearly advantageous for 
many viruses although TP53 mutations are a rare event [163]. 
 
3.3TP53 AND EPSTEIN-BARR VIRUS 
Until now, five EBV-encoded viral proteins have been shown to interact with p53: BZLF1, 
EBNA-LP and EBNA3C are capable of bind to p53 and directly interact with the protein; and 
LMP1 and EBNA1 who are implicated in indirect modulation p53 expression [166-169]. 
BZLF1 immediate-early protein, which is an important modulator of p53 function, binds to 
the C-terminus of p53 through its sequences in the C-terminus dimerization domain, inhibiting 
p53 transcriptional function and enhancing the ubiquitin-mediated degradation of p53 [167, 
170]. However, the effect of BZLF1 on p53 function is controversial, with some studies reporting 
that BZLF1 increases the level of cellular p53 and enhances p53 transactivation function [171, 
172]. The underlying mechanisms of BZLF1 interaction with p53 are still unclear but it is 
possible that BZLF1 has both activating and inhibitory effects on p53. This dual contradictory 
function could be the result of cell type-dependent effects of BZLF1 on p53 function or the 
influence of other viral proteins, whose presence might alter the effect of BZLF1 on p53 [173]. 
EBNA5, also referred to as EBNA-LP, deregulates cell cycle progression through binding to 
both Rb and p53 [166]. Recent studies have suggested that EBNA5 binds to p14ARF and 
MDM2, two proteins involved in p53 regulation, resulting in the downregulation of p53 levels in 
infected B cells. Furthermore, these studies hypothesis that inhibition of p53 transactivation 
function is due to formation of trimolecular complexes between EBNA5, MDM2 and p53 [174, 
175]. 
LMP1 role in p53 expression seems to be contradictory, while some report that LMP1  can 
induce p53 degradation other defend that contributes to its stability and accumulation [168, 
176]. Husaini et al.  refers that LMP1 overexpression lead to increased polyubiquitination of 
p53, suggesting that decrease of p53 protein levels by LMP1 was due to increased degradation 
of the protein [168]. Contrarily, Li et al. describes that LMP1 promotes p53 
accumulation/stability and transcriptional activity through a distinct ubiquitination process, the 
K63-linked ubiquitination, that results in cell cycle arrest  and escape of apoptosis by tumor 
cells [176]. 
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EBNA1 indirectly regulates p53 through ubiquitin-specific-processing protease 7 (USP7). 
USP7 is a direct MDM2 antagonist and its overexpression stabilizes p53, leading to p53-
mediated growth repression and apoptosis [177]. In EBV-infected cells, EBNA1 binds to USP7 
ten times more strongly than p53, interfering with p53 stabilization, and therefore indirectly 
destabilize p53 contributing for cell immortalization, proliferation and survival of the latently 
infected cells [178]. 
EBNA3C contributes to MDM2 stabilization and cellular accumulation by direct binding and 
deubiquitination of this protein. In turn, this event facilitates p53 ubiquitination and, 
consequently, its degradation. The repression of p53 function by EBNA3C may augment the 
efficiency of EBV-mediated cellular transformation [179, 180]. 
Together, these five EBV proteins mediate the virus interaction with p53 protein, contributing 
to decreased apoptosis and cell cycle arrest that ultimately promotes proliferation and survival 
of infected cells and contribute to EBV-mediated carcinogenesis [181]. 
In contrast to the majority of epithelial malignancies, TP53 mutations are an infrequent event 
in EBV-associated neoplasias [34]. In nasopharyngeal carcinomas mutations of TP53 are a 
rare event, occurring in less than 10% of all cases [182-184]. However, p53 overexpression 
has been reported in more than 85% of NPC cases [185, 186]. Although the reason for high 
p53 levels in NPC is unclear, these findings suggest that other mechanisms different from 
mutations, such as epigenetic modulation induced by EBV proteins, are responsible for p53 
overexpression [187, 188]. In gastric cancer, p53 pathway dysregulation is due to mutations 
of p53 in approximately 70% of all cases [137, 189]. In contrast, in EBV-associated gastric 
cancer mutations in p53 are infrequent but CpG islands methylation is a common event 
suggesting that aberrant methylation might be an important mechanism of EBV-related gastric 
carcinogenesis [137, 138]. Additionally, EBVaGC had lower rate of p53 overexpression than 
gastric cancer non-associated with EBV indicating that abnormal p53 expression could be  
associated with EBV infection [190]. 
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Although there are a few studies regarding p53 accumulation in EBV-associated neoplasias, 
there are no data on p53 mRNA expression in these tumors and moreover there is a lack of 
clarification concerning the influence of EBV on p53 modulation in neoplasias. 
The aim of this study is to characterize p53 accumulation and mRNA expression in EBV-
associated epithelial tumors: gastric and nasopharyngeal carcinomas. 
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1.Study Population  
A retrospective study was performed using 53 patients attended at Portuguese Oncology 
Institute of Porto (IPO-Porto): 10 with EBV-associated NPC and 43 with GC, being 12 EBV-
positive and 31 EBV-negative. All cases were histologically confirmed by a pathologist from our 
institution and categorized according to the WHO classification systems for each type of cancer. 
NPC cases were randomly selected from a cohort of patients of our institution [23, 24]. GC 
cases were selected from a cohort of patients diagnosed with GC in 2011 in our institution 
(unpublished data), including 12 EBV-positive cases and 31 matched (histological type, age 
and stage of disease) EBV-negative cases. Positive cases were detected using in situ  
hybridization for the detection of EBV-encoded small RNA (EBER-ISH). Tumor tissues samples 
were collected from the institution archives and histological sections from formalin-fixed 
paraffin-embedded (FFPE) tissue blocks were used for immunohistochemistry and for RNA 
extraction. This study did not interfere with clinical decisions. Clinicopathological data was 
collected from individual clinical records and inserted on a database with unique codification. 
All 111 procedures were approved by the ethical committee of IPO Porto (CES IPO 74/2015). 
 
 
1.1. Characterization of Population 
NPC group of patients (n=10) included 7 males and 3 females with mean age of 51 years 
old. All NPC cases were undifferentiated nonkeratinizing carcinomas (Table 3). 
EBVaGC group of patients (n=12) included 9 males and 3 females with mean age of 69 
years old. In this group, half of the cases were tubular adenocarcinomas and the other half 
were distributed by the other histological subtypes. Regarding tumor localization the EBVaGC 
were evenly distributed (Table 4). 
EBVnGC group of patients (n=31) included 18 males and 13 females with mean age of 63 
years old. EBVnGC were equally distributed by histological subtypes. This group was also 
characterized by a predominance of antral tumor localization and infiltrative invasion pattern 
(Table 4). 
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Table 3. Characterization of nasopharyngeal carcinoma cases 
 NPC 
Gender n (%) 
Male 7 (70.0%) 
Female 3 (30.0%) 
Age  
Mean± sd 51±16.1 
Maximum 74 
Minimum 20 
Global Stage n (%) 
II 1 (10.0%) 
III 2 (20.0%) 
IVa 3 (30.0%) 
IVb 1 (10.0%) 
IVc 2 (20.0%) 
Missing 1 (10.0%) 
NPC, nasopharyngeal carcinoma. 
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Table 4. Characterization of gastric carcinoma cases. 
 EBVaGC EBVnGC 
Gender n (%) n (%) 
Male 9 (75.0%) 18 (58.1%) 
Female 3 (25.0%) 13(41.9%) 
Age   
Mean ± sd 69±9.62 63±9.86 
Range  52- 82 40- 81 
Histology WHO n (%) n (%) 
Mixed adenocarcinoma 2 (16.7%) 10 (32.3%) 
Tubular adenocarcinoma 6 (50.0%) 10 (32.3%) 
Poorly cohesive carcinoma 1 (8.3%) 11 (35.4%) 
Carcinoma with lymphoid stroma 2 (16.7%) - 
Adenosquamous carcinoma 1 (8.3%) - 
Tumor Localization n (%) n (%) 
Antrum 3 (25.0%) 20 (64.5%) 
Cardia 2 (16.7%) 3 (9.7%) 
Body 4 (33.3%) 8 (25.8%) 
Pylorus 1 (8.3%) - 
Missing 2 (16.7%) - 
Invasion Pattern n (%) n (%) 
Expansive 6 (50.0%) 8 (25.8%) 
Infiltrative 3 (25.0%) 22 (71.0%) 
Missing 3 (25.0%) 1 (3.2%) 
Global Stage n (%) n (%) 
Ia 1 (8.3%) 7 (22.6%) 
Ib 2 (16.7%) 1 (3.2) 
IIa 2 (16.7%) 3 (9.6%) 
IIb 1 (8.3%) 6 (19.7%) 
IIIa 5 (41.7%) 4 (12.8%) 
IIIb 1 (8.3%) 5 (16.1%) 
IIIc - 3 (9.6%) 
IV - 2 (6.4%) 
EBVaGC, EBV-associated gastric carcinoma; EBVnGC, EBV non-associated gastric carcinoma. 
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2.p53 accumulation  
IHC was used to investigate the accumulation of p53 protein, using 3 μm sections from  
FFPE tissue blocks with the monoclonal antibody DO-7 (DAKO, Glostrup, Denmark).  Tissue 
samples were submitted to deparaffinization/rehydration using the following sequence: xylene 
for 2 x 4 minutes; 100% v/v ethanol for 2 x 4 minutes; 96% v/v ethanol for 2x4 minutes; 70% 
v/v ethanol for 4 minutes and water for 5 minutes. After that, antigen retrieval was performed 
using a heat induced epitope retrieval method, where the slides were submersed in a citrate-
based antigen unmasking solution (VECTOR, Burlingame, CA 121 USA) and heated in the 
microwave for 15 minutes at medium power. Slides were allowed to cold down to room 
temperature, rinsed in the unmasking solution for almost 30 minutes. Then, samples were 
washed in phosphate-buffered saline (PBS) containing 0.02% Tween 20 (PBS-T) and the 
endogenous peroxidase was blocked with 3% hydrogen peroxide (H2O2) for 10 minutes. 
Subsequently, the slides were washed 2x in PBS-T for 5 minutes, 126 treated with UV-block 
solution from UltraVision Large Volume Detection System Anti- 127 Polyvalent, HRP 
(THERMO SCIENTIFIC, Fremont, USA) for 10 minutes to block nonspecific protein binding and 
incubated overnight at 4ºC with DO-7 mouse anti-human p53 monoclonal antibody diluted 
1:200 (DAKO, Glostrup, Denmark). Slides were then rinsed in PBS-T, incubated with 
Biotinylated Goat Anti-Polyvalent Antibody (THERMO SCIENTIFIC, Fremont, USA) in a humid 
chamber at room temperature for 10 minutes, washed 2x with PBS-T for 5 minutes and 
incubated with Streptavidin Peroxidase  (THERMO SCIENTIFIC, Fremont, USA) for 10 minutes 
at room temperature. Detection of hybrids was achieved by an enzymatic reaction using 3,3'-
diaminobenzidine (DAB) ImmPACTTM DAB (VECTOR, Burlingame, CA USA) diluted at 3:100 
and incubated during 4 minutes at room temperature. The final wash was performed with 
distilled water for 5 minutes. Mayer’s hemalum solution (Millipore, Darmstadt, Germany) was 
used as counterstain. After coloration, slides were washed in running water for 5 minutes and 
the following step was sequential dehydration in 70% v/v ethanol for 4 minutes, 96% v/v ethanol 
for 2 x 4 minutes, 100% v/v ethanol for 2 x 4 minutes and xylene for 2 x 4 minutes. Mounting 
was performed with Microscopy Entellan (MERCK, Darmstadt, Germany). Nuclear p53 
accumulation was defined as negative (>5% cells). Tumors with positive p53 staining were 
semi-quantitatively categorized into four categories: 5-25%, 25-50%, 50-75% and >75% of 
nuclei staining positive. 
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3.TP53 mRNA expression  
RNA was extracted from 10 μm sections using the Absolutely RNA FFPE Kit (Agilent 
Technologies, San Diego CA, USA) and quantified using the NanoDrop 1000  
Spectrophotometer v3.7 (Thermo Scientific, Wilmington DE, USA). TP53 and GAPDH were 
analyzed by two-step real-time PCR using hs01034249_m1 and hs02758991_g1 TaqMan 
Gene Expression Assays (Applied Biosystems, Foster CA, USA), respectively. Reverse 
transcriptase reactions, with 20 μL final volume, were performed using High-Capacity cDNA 
Reverse Transcription Kit (PN 4368814; Applied Biosystems, Foster CA, USA) according to 
the manufacturer's instructions. The amplification conditions were as follows: annealing at 25ºC 
for 10 min, extension at 37ºC for 120 min and RT inactivation at 85ºC for 5 min. All reverse 
transcriptase reactions included no-template controls. qPCRs were performed in duplicates in 
independent reactions with a 10μl final volume mixture containing 1X of TaqMan® Universal 
PCR Master Mix (Applied Biosystems, Foster City, California USA), 1X RNA Assay (Applied 
Biosystems, Foster City, California USA), and 10-100 ng of cDNA (RT product). Amplification 
was run in Applied Biosystems Step-One Real Time PCR System (Applied Biosystems, Foster 
CA, USA) with the following thermal cycling conditions: 10 min at 95°C followed by 45 cycles 
of 15 sec at 95°C and 1 min at 60°C. The relative quantification of p53 expression was analyzed 
using the 2-ΔΔCt method, also known as Livak method. In this method, Ct from the target RNA 
(p53) in both test and control cases were adjusted in relation to the Ct of a normalizer RNA 
(GAPDH) resulting in ΔCt. For the comparison between EBVaGC and EBVnGC we have 
calculated ΔΔCt value, which allows us to determine the differences in p53 expression. 
 
 
4.Statistical analysis  
Results were analysed using the computer software IBM SPSS Statistics for Windows, 
Version 22.0 (IBM Corp, Armonk NY, USA). Data from all cases were compared by Student’s 
t-test and ANOVA considering a statistical significance of 5% (p<0.05). 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS
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1. p53 accumulation  
The results from IHC analysis are shown in Table 5 and Figure 11 where is described, for 
each group, the percentage of cells with p53 accumulation/reactivity. Figure 12 illustrates 
examples of p53 accumulation in the different groups. All cases included in this study, except 
one GC case, were positive for the presence of p53 accumulation by immunohistochemistry. 
NPC cases are a homogeneous group, with all samples having more than half of cells with p53 
accumulation: 3 cases (30%) showed 50-75% of cells with p53 accumulation and 7 (70%) 
presented more than 75% of cells with p53 accumulation. In EBVnGC cases, p53 was 
frequently found with 16.7%, 33.3%, 26.7% and 23.3% of cases found with 5-25%, 25-50%, 
50-75%, and >75% of accumulation, respectively. Similarly to NPC, EBVaGC showed a strong 
p53 accumulation, with 58.3% of cases having more than 75% of cells with p53 accumulation, 
16.7% with 50-75% and only 25% having less than 50% of cell with p53 accumulation. Results 
showed that p53 accumulation in NPC and EBVaGC is not significantly different (p=0.501) 
while there is a statistically significant difference between EBVaGC and EBVnGC (p=0.027). 
Regardless of EBV status, the analysis of all gastric cancer cases revealed that there is no 
statistical differences between the histological subtypes in the p53 accumulation in tissue 
(p=0.856) (data not shown). Similarly, the comparison of all gastric cancer cases according to 
tumor localization and invasion pattern indicated no statistical differences in the expression of 
p53 (p=0.723 and p=0.171, respectively) (data not shown). 
 
Table 5. Distribution of percentage of cells with p53 accumulation in nasopharyngeal and gastric carcinomas 
 Percentage of cells 
 
5-25%  
n(%) 
25-50%  
n(%) 
50-75%  
n(%) 
>75% 
 n(%) 
EBVnGC (n=30) 5 (16.7) 10 (33.3) 8 (26.7) 7 (23.3) 
EBVaGC (n=12) 2 (16.7) 1 (8.3) 2 (16.7) 7 (58.3) 
NPC (n=10) 0 (0.0) 0 (0.0) 3 (30.0) 7 (70.0) 
Total 7 (13.4) 11 (21.2) 13 (25.0) 21 (40.4) 
EBVaGC, EBV-associated gastric carcinoma; EBVnGC, EBV non-associated gastric carcinoma; NPC, nasopharyngeal carcinoma. 
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Figure 11. Percentage of cells with p53 accumulation in nasopharyngeal and gastric carcinomas. 
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Figure 12. Expression of EBERs and p53 in NPC, EBV-associated and EBV-negative gastric cancers. 
A-B) EBER-ISH positive staining in NPC and EBVaGC; 
C) Negative result of EBER-ISH in EBVnGC; 
D-F) Representative tumors with strong p53 accumulation. 
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2. TP53 mRNA expression 
The results from qPCR analysis are shown in Table 6. TP53 mRNA and GAPDH mRNA 
(reference gene) were evaluated for all cases and 6 (1 NPC and 5 EBVnGC) were excluded of 
the analysis because TP53 mRNA expression was not detected. The analysis of NPC cases 
revealed the presence of TP53 mRNA – Figure 13. When analysing the expression of TP53 in 
EBVaGC, we observed a significant decrease (2-ΔΔCt=0.21; p=0.010) in TP53 mRNA expression 
in comparison with EBVnGC – Figure 13. Further analysis subdividing EBVnGC according to 
histological subtypes revealed that EBVaGC TP53 mRNA expression was significantly 
decreased when compared with EBVnGC poorly cohesive and EBVnGC tubular histological 
subtypes (2-ΔΔCt=0.11; p<0.001 and 2-ΔΔCt=0.20; p=0.008, respectively); despite not statistically 
significant, the reduction of expression also occurs when comparing with EBVnGC mixed types 
(2-ΔΔCt=0.43; p=0.162) - Figure 13. Moreover, the comparison of TP53 mRNA expression 
between GC histological subtypes, regardless of EBV status, revealed a difference with 
statistical significance between mixed adenocarcinomas and poorly cohesive carcinomas (2-
ΔΔCt=0.27; p=0.014). In addition, the analysis of GC cases according to tumor localization and 
invasion pattern indicated no statistical significant differences in TP53 mRNA expression. 
 
Table 6.  qPCR data analysis and expression profile data for TP53 mRNA in nasopharyngeal and gastric cancers 
 
 Ct GAPDH VC Ct TP53  VC 
ΔCt ± sd 
(range) 
EBVaGC (n=12) 
26.31 ± 1.19 
(24.27 – 27.97) 
0.05 
34.42 ± 1.59 
(31.78 – 36.68) 
0.05 
8.10 ± 1.83 
(3.84 – 10.34) 
EBVnGC (n=26) 
28.06 ± 2.51 
(23.41 – 34.57) 
0.09 
33.90 ± 1.69 
(30.49 – 37.27) 
0.05 
5.84 ± 1.73 
(2.71 – 10.61) 
EBVnGC poorly cohesive (n=9) 
29.71 ± 1.69 
(27.29 – 32.60) 
0.06 
34.68 ± 1.24 
(32.53 – 36.25) 
0.04 
4.97 ± 1.20 
(3.60 – 7.35) 
EBVnGC tubular (n=9) 
27.07 ± 3.16 
(23.41 – 34.57) 
0.12 
32.86 ± 1.95 
(30.49 – 37.27) 
0.06 
5.80 ± 1.72 
(2.71 – 8.93) 
EBVnGC mixed (n=8) 
27.31 ± 1.58 
(25.29 – 30.10) 
0.06 
34.19 ± 1.35 
(32.36 – 35.90) 
0.04 
6.88 ± 1.86 
(4.41 – 10.61) 
NPC (n=9) 
27.83 ± 1.55 
(25.14 – 29.76) 
0.05 
33.39 ± 1.74 
(30.51 – 36.08) 
0.05 
5.56 ± 1.06 
(4.07 – 7.19) 
Ct, cycle threshold; sd, standard deviation; VC, variation coefficient; EBVaGC, EBV-associated gastric carcinoma; EBVnGC, EBV 
non-associated gastric carcinoma; NPC, nasopharyngeal carcinoma. 
Mariana Malta | MSc Oncology
48 | Mechanisms of silencing TP53 in EBV-related neoplasias
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
2
4
6
8
10
12
EBVaGC EBVnGC EBVnGC poorly
cohesive
EBVnGC tubular EBVnGC mixed NPC
∆
C
t
2
-∆∆Ct
= 0.021 ; p=0.010 
2
-∆∆Ct
= 0.011 ; p<0.001 
2
-∆∆Ct
= 0.020 ; p=0.008  
2
-∆∆Ct
= 0.043 ; p=0.162  
Figure 13. Expression profile of TP53 mRNA in nasopharyngeal and gastric carcinomas. 
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Despite the great number of genes involved in human carcinogenesis, TP53 gene has been 
considered as one of the most important genes, being crucial in the regulation of signalling 
processes of tumor development [191]. The p53 protein is activated in response to endogenous 
or exogenous stresses, inducing cell cycle arrest, DNA repair, apoptosis and senescence of 
cells [142]. Therefore, the modulation of TP53 is considered a key hallmark for cancer 
development and there are several mechanisms that contribute for its deregulation [191]. TP53 
gene mutations are one of the most frequent alterations in human cancers, occurring in almost 
every type of cancer at rate of 10% to 100% [142, 161]. Furthermore, viruses have been 
considered as able to modulate p53 pathway, either by direct inactivation of the protein or by 
gene-gene interaction [160]. 
EBV, a ubiquitous herpesvirus, infects approximately 90% of the human adult population 
worldwide, being the infection asymptomatic in the majority of lifelong carriers [10]. Based on 
its role in the development of malignant disorders, EBV has been classified as a group 1 
carcinogen by the International Agency for Research on Cancer (IARC) [34, 192].  
EBV has been described in the pathogenesis of lymphoproliferative disorders as well as 
epithelial malignancies such as NPC and GC [19, 58]. One of the potential targets of EBV in 
carcinogenesis processes is the p53 pathway and previous studies have shown that the 
frequency of TP53 gene mutations in EBV-associated neoplasias is low [137, 138, 182-184] . 
In fact, TP53 is rarely mutated suggesting that other mechanisms different from mutations could 
be responsible for p53 deregulation [187, 188]. Understanding the mechanisms of EBV-
associated p53 deregulation in these cancers would allow a better knowledge of the 
carcinogenesis model in epithelial tumors. 
In our study, the detection of p53 accumulation was performed by IHC for p53 using the DO-
7 antibody, that recognizes both wild-type and mutant forms of p53 [193]. This is a cheap and 
rapid method widely used in routine procedures, being the commonest method to infer TP53 
mutational status in ovarian carcinoma [194] since it is more likely to detect mutated p53 due 
to its longer half-life usually considering that is related to TP53 gene mutation [195]. However, 
in other models studies that have used IHC as a surrogate marker for TP53 mutation have 
failed to demonstrate consistent results [161]  by showing a large number of misclassified cases 
(false-positive and false-negative) [161, 196]. In our study p53 staining was nuclear in tumor 
cells and absent in normal cells. Nuclear p53 staining was classified as p53 accumulation and 
this accumulation could not be directly correlated with TP53 mutations. Alterations in p53 
signalling pathway might lead to functional p53 stabilization or inhibition of p53 degradation, 
ultimately resulting in p53 accumulation not related to TP53 mutations [197].  
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Concerning NPC, we have found p53 accumulation in 100% of cases and all of them showed 
more than 50% of cells with p53 accumulation. Previous studies also showed a high p53 
accumulation, ranging between 64.7% and 95.9% [185, 186, 188, 198-202]. The relationship 
between accumulation of p53 in NPC and EBV infection is still controversial [185, 188, 199-
201]. Although the mechanism by which EBV induced p53 expression has not been elucidated, 
some authors suggested that LMP1, a highly expressed EBV-latent protein in NPC, seem to 
be responsible for p53 accumulation in NPC without TP53 gene mutation [108]. Indeed, LMP1 
seems to induce wild-type p53 stabilization through the promotion of K63-linked ubiquitination, 
which is a cellular pathway regulator and thus enhancing the half-life of the protein [176, 203]. 
Furthermore, LMP1 also blocks MDM2-mediated p53 degradation through the suppression of 
K48-linked ubiquitination [176]. Together this dual function of LMP1 could explain the wild-type 
p53 accumulation in NPC tissue [176]. 
Regarding p53 accumulation in GC, our study revealed an overall high rate of p53 
accumulation (100% in EBVaGC and 96.7% in EBVnGC). Similar results were found by other 
authors: Wang et al. reported a high p53 accumulation in both EBVaGC (84.6%) and EBVnGC 
(86.7%) [190] ; and Kim et al. showed more p53 accumulation in EBVaGC (100%) compared 
to EBVnGC (85.0%) and with a predominance of >50% of cells with p53 accumulation in both 
EBVaGC (83.3%) and EBVnGC (75.0%) [204]. Other studies showed contradictory results 
reporting less p53 accumulation in EBVaGC compared to EBVnGC [205-207] and one meta-
analysis study demonstrated a lower rate of p53 accumulation, although not statistical 
significant, in EBVaGC (36.2%) when compared with in EBVnGC (47.9%) [208]. Our results 
also showed a significant difference of p53 accumulation in EBVaGC comparing with EBVnGC 
(p=0.027), with p53 accumulation in more than 50% of cells in 9/12 EBVaGC comparing with 
an equally distribution between p53 accumulation groups in EBVnGC. Contrarily to other 
studies, our data seems to indicate that the percentage of cells with p53 accumulation in gastric 
cancer is dependent of EBV infection [209-211]. 
In the present study, comparison of gastric cancers, regardless of EBV status, revealed no 
differences in terms of p53 accumulation between tumor histology subtypes. With the exception 
of two studies that reported no significant association between the histology of tumor and p53 
accumulation [212, 213], the majority of publications found a significant correlation of 
histological subtype with p53 accumulation in gastric cancer tissue [214-216].  All these reports 
utilized Lauren's histological classification, comparing intestinal and diffuse type. Accumulation 
of p53 occurred significantly more in the intestinal type, with p53 accumulation in 55.9% of 
intestinal type and 27.3% of diffuse type [214, 216]. Although our results were not statistically 
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different, we found that the majority (58.3%) of tubular adenocarcinomas (Lauren's intestinal 
type) had more than 50% of cells with p53 accumulation while 66.7% of poorly cohesive 
carcinomas (Lauren's diffuse type) had less than 50% of cells with p53 accumulation. 
The results regarding p53 accumulation according to tumor localization and invasion pattern 
also showed no statistical differences, which is in agreement  with the literature, suggesting 
that neither tumor location or invasion pattern influence p53 accumulation in gastric cancer 
tissue [212, 217]. 
In order to better understand if the accumulation of p53 was a consequence of increased 
TP53 transcription, we have also investigated the TP53 mRNA by qRT-PCR. As far as we 
know, this is the first study using qRT-PCR methodology to evaluate the levels of TP53 gene 
expression in EBVaGC.  
Among GC, we found a significant decrease in TP53 mRNA expression in EBVaGC, which 
had less 80% of TP53 mRNA expression when compared with EBVnGC. A further subdivision 
of EBVnGC in different histological subgroups showed that EBVaGC had a significant 
downregulation of TP53 mRNA expression independent of histological subtypes. This result 
could be explained by the potential of some EBV latent proteins to destabilize p53: EBNA1 has 
been described to compete with p53 for the same binding site of USP7, a cellular ubiquitin-
specific protease that has been reported to bind and regulate p53, and its higher affinity 
interferes with the stabilization of p53 contributing for lower p53 levels [104, 218, 219]; EBNA3C 
reported as capable to directly bind p53 and repress its apoptotic and transcriptional activities 
[179]; and EBNA5, which  is capable of binding to p14ARF and MDM2, two proteins involved 
in p53 regulation, resulting in the downregulation of p53 levels by the formation of trimolecular 
complexes between EBNA-5, MDM2 and p53 [174, 175]. Therefore, EBNA1, EBNA3C, EBNA5 
or the combined effect of these three EBV proteins could be the cause of decrease in TP53 
mRNA expression that we found in EBVaGC. Although there are no previous studies, taking 
into account that deregulations induced by these EBV latent proteins do not always lead to p53 
degradation, they could also be responsible for p53 accumulation in cells. Due to this interaction 
of EBV proteins with p53, it will be important to evaluate the TP53 mutational status to 
understand if p53 accumulation is a result or not of TP53 mutations in EBV-positive cells.Our 
results are mostly important to corroborate the idea that with the current knowledge on 
molecular features of GC, histological classification has limited value to distinguish these 
tumors. In fact, due to the heterogeneity of GC, a new classification based on molecular 
features of tumors have been proposed, with EBVaGC categorized as a "new" and distinct 
subtype of gastric cancer [137, 138]. In addition, Cristescu et al. proposed a new classification 
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wherein p53 status has a pivotal role: TP53+ (without TP53 gene mutation) and TP53- (with 
TP53 gene mutations). Interestingly the group of TP53+ was closely linked to EBV infection 
and had a better overall survival [220]. These data is in accordance with previous reports of no 
TP53 mutations in EBV positive gastric carcinomas [137, 138]. Our study gives new insight on 
modulation of p53 by EBV but further studies are needed in order to understand the 
mechanisms by which EBV modulates p53 expression and accumulation in cells. 
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In EBV-associated epithelial malignancies, p53 is differently modulated comparing to non-
viral neoplasias, whereas TP53 mutations are common. With this study, it was possible to 
confirm that in our population all NPC and EBVaGC had p53 accumulation in tissue and 
EBVaGC and EBVnGC had a significant difference of p53 accumulation. We were also able to 
identify that EBVaGC had a significant decrease of TP53 mRNA comparing with EBVnGC. 
Our results gave new insight in the molecular features of NPC and EBVaGC and 
demonstrated that p53 is not differently accumulated or expressed according to the histological 
groups. This data corroborate previous studies defending that classification of gastric 
carcinomas based on histology is a method with limited utility and that propose a new gastric 
cancer classification based on its molecular features [138]. 
Furthermore, our results demonstrated that although EBV-associated neoplasias showed 
p53 accumulation, in EBVaGC TP53 mRNA seems to be significantly diminished when 
compared to EBV non-associated neoplasias. These findings support the hypothesis that the 
carcinogenesis mechanism is different depending if the tumor is associated or not to EBV. 
This is the first study regarding TP53 mRNA expression in EBVaGC and further studies are 
required to confirm these evidences, especially with different populations. It is also important 
to study the mutational status of TP53 gene to know if the p53 accumulation found in this work 
is related or not with mutations in this gene. Additionally, it would be interesting to study other 
genes in order to understand the mechanisms by which EBV modulates both oncogenes and 
tumor suppressor genes to promote carcinogenesis. 
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p53 EXPRESSION IN EPSTEIN-BARR VIRUS ASSOCIATED GASTRIC CANCER AND 
NASOPHARYNGEAL CARCINOMA
THU-PS10-30
p53 accumulation is observed in all EBV-associated epithelial malignancies and in 96.8% EBV-negative gastric
cancers. However, our study revealed that p53 mRNA expression decreases significantly when comparing EBV-
positive and EBV-negative gastric carcinomas. These results suggest that EBV-mediated carcinogenesis
interferes with p53 pathway.
In addition, NPC and EBVaGC were characterized by different profiles of LMP1 and LMP2a expression
suggesting a distinct EBV-mediated carcinogenesis.
Conclusion
IHC for p53 showed its accumulation in all cases with the exception of one EBV non-associated gastric cancer
(EBVnGC) that was negative. The EBVnGC cases were uniformly distributed between the four groups of
percentages while EBVaGC and NPC showed a strong p53 accumulation (Figure 1). The majority of EBVaGC
cases had more than 75% of cells with p53 accumulation. The NPC cases form a homogeneous group, with all
samples having more than 50% of cells with p53 accumulation.
In contrast, qRT-PCR results revealed a significant decreased expression of TP53 mRNA in EBVaGC (2-ΔΔCt=0.21;
p=0.010) when compared with EBVnGC (Table 1). In all NPC cases the presence of TP53 mRNA was also
observed.
The expression analysis of LMP1 and LMP2a in EBVaGC and NPC tumors, demonstrated different profiles.
LMP1 is expressed in all NPC and in none of EBVaGC cases, while LMP2a is present in 100% and 58.3%,
respectively (Figure 2; Figure 3).
Results
Figure 1: Percentage of cells with p53 accumulation in different neoplasias.
n=2 n=5
n=1
n=10
n=3
n=2
n=8n=7
n=7
n=7
NPC EBVaGC EBVnGC
5-25% 25-50% 50-75 >75%
ΔCt ± sd 2-∆∆Ct p value
EBVnGC (n=26) 5.84 ± 1.73 Reference (1) -----
EBVaGC (n=12) 8.10 ± 1.83 0.21 0.010
Table 1: Expression profile data for p53 mRNA in gastric cancer.
100.0%
0.0%
100.0%
58.3%
NPC EBVaGC
LMP1 LMP2a
Figure 3: Percentage of cases with LMP1 and LMP2a expression in NPC 
and EBVaGC.
Epstein-Barr virus (EBV) is a human cancer-
associated virus that infects approximately 90% of
the human adult population worldwide.
Nevertheless, EBV has a great carcinogenic potential
and has been associated with epithelial tumours
such as Nasopharyngeal Carcinoma (NPC) and more
recently to Gastric Carcinoma.
The development of EBV-associated malignancies is
dependent on the expression of viral proteins, such
as LMP1 and LMP2a, that modulate multiple
signalling pathways.
TP53 is a tumour suppressor gene frequently
mutated in human cancers. However, in EBV-
associated epithelial malignancies TP53 mutations
are uncommon, suggesting that other mechanisms
different from mutations could be responsible for
p53 deregulation .
This study aimed to evaluate p53 accumulation and
mRNA expression in NPC and EBV-associated gastric
carcinoma (EBVaGC) tissues and compare with EBV
LMP1 and LMP2a expression in tumours.
Introduction
p53 expression and accumulation was evaluated in
3 groups of patients: 10 with EBV-associated NPC
(mean age: 51±16); 12 EBVaGC (mean age:
64±10) and 31 EBV non-associated gastric
carcinomas (EBVnGC) (mean age: 63±10).
The expression of p53 mRNA was evaluated by qRT-
PCR and its relative quantification was determined
using the Livak method, with GAPDH mRNA as
normalizer.
Accumulation of p53 and LMP1 and LMP2a
expression were assessed by immunohistochemistry
(IHC) using monoclonal antibodies (DO-7, NCLEBV-
CS1-4 and 15F9, respectively). LMP1 and LMP2a
expression was classified as positive or negative.
Nuclear p53 accumulation was defined as negative
(<5% cell) or positive (>5% cells). Tumours with
positive p53 staining were semi-quantitatively
categorized into four groups as follows: 5-25%, 25-
50%, 50-75% and >75% of nuclei staining positive.
Methods
Figure 2: Examples of  immunohistochemistry on 
EBVaGC: A. EBERs; B. p53; C. LMP1; D. LMP2a.
A B
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&,,323 ϭϮ
'HSDUWPHQW RI 3DWKRORJ\ DQG 9LURORJ\ 6HUYLFH 3RUWXJXHVH2QFRORJ\ ,QVWLWXWH RI 3RUWRϭϯ
)*(3(5XD'U$QWyQLR%HUQDUGLQRGH$OPHLGD3RUWR32578*$/ϭϰ
5HVHDUFK 'HSDUWPHQW 3RUWXJXHVH /HDJXH $JDLQVW &DQFHU /3&&151RUWH (VWUDGDϭϱ
,QWHULRUGD&LUFXQYDODomR3RUWR32578*$/ϭϲ
7KHVHDXWKRUVFRQWULEXWHGHTXDOO\LQWKHVWXG\ϭϳ
ϭϴ
&RUUHVSRQGHQFHWRϭϵ
+XJR6RXVD0'3K'ϮϬ
6HUYLoRGH9LURORJLD±/DERUDWyULRV3LVRϮϭ
,QVWLWXWR3RUWXJXrVGH2QFRORJLDGR3RUWR)*(3(ϮϮ
5XD'U$QWyQLR%HUQDUGLQR$OPHLGDϮϯ
3RUWR32578*$/Ϯϰ
3KRQHH[W)D[Ϯϱ
(PDLOKXJRPOV#JPDLOFRPRUKXJRVRXVD#LSRSRUWRPLQVDXGHSWϮϲ
$EVWUDFWZRUGFRXQWZRUGV 7H[WZRUGFRXQWZRUGVϮϳ
)LJXUHVQXPEHU 7DEOHVQXPEHUϮϴ
 Ϯ
$%675$&7ZRUGVϮϵ
%DFNJURXQG (SVWHLQ%DUU YLUXV (%9 KDV EHHQ DVVRFLDWHG ZLWK WKH GHYHORSPHQW RIϯϬ
HSLWKHOLDO WXPRUVVXFKDV1DVRSKDU\QJHDO&DUFLQRPD13&DQGPRUHUHFHQWO\WR*DVWULFϯϭ
&DUFLQRPD*&TP53LVDWXPRUVXSSUHVVRUJHQHIUHTXHQWO\PXWDWHGLQKXPDQFDQFHUVϯϮ
QHYHUWKHOHVV LQ (%9DVVRFLDWHG HSLWKHOLDO PDOLJQDQFLHV PXWDWLRQV DUH XQFRPPRQ HYHQϯϯ
ZLWKIUHTXHQWGHUHJXODWLRQRIWKHSSDWKZD\,QWKLVVWXG\ZHDLPHGWRFKDUDFWHUL]HSϯϰ
DFFXPXODWLRQ DQG P51$ H[SUHVVLRQ LQ 13& DQG (%9DVVRFLDWHG JDVWULF FDUFLQRPDϯϱ
(%9D*&WLVVXHVϯϲ
0HWKRGV S H[SUHVVLRQ DQG DFFXPXODWLRQ ZDV HYDOXDWHG E\ T573&5 DQGϯϳ
LPPXQRKLVWRFKHPLVWU\ ,+& LQ D UHWURVSHFWLYH VWXG\ ZLWK WLVVXHV IURP  13& ϯϴ
(%9D*&DQG(%9QHJDWLYH*&(%9Q*&FDVHVϯϵ
5HVXOWV ,+& VKRZHG WKDW S LV DFFXPXODWHG LQ *& DQG DOO 13& FDVHVZLWKϰϬ
PRUHWKDQRIFDVHVVKRZLQJRIFHOOVZLWKSDFFXPXODWLRQ7KLVKLJKUDWHRIϰϭ
S DFFXPXODWLRQ ZDV PRUH FRPPRQ LQ 13& DQG (%9D*& UDWKHU WKDQ (%9Q*&ϰϮ
5HJDUGLQJWKHH[SUHVVLRQRI73LQ13&LWZDVREVHUYHGWKHSUHVHQFHRI73P51$ϰϯ
)XUWKHUPRUHLQ*&WKHTP53H[SUHVVLRQDQDO\VLVUHYHDOHGWKDWWKHOHYHOVRI73P51$ϰϰ
LQ(%9D*&DUHDOPRVWORZHUǻǻ&W p ZKHQFRPSDUHGZLWK(%9Q*&ϰϱ
DQGWKHVHUHVXOWVZHUHLQGHSHQGHQWRIWKHKLVWRORJLFDOVXEW\SHVϰϲ
&RQFOXVLRQ2XU UHVXOWV VKRZHG WKDW S DFFXPXODWLRQZDV REVHUYHG LQ RI(%9ϰϳ
DVVRFLDWHG HSLWKHOLDOPDOLJQDQFLHV 13& DQG (%9D*& DQG LQ  RI (%9Q*& 7KHϰϴ
VLJQLILFDQWGHFUHDVHRITP53P51$LQ(%9D*&FRPSDULQJZLWK(%9Q*&VXJJHVWVWKDWϰϵ
YLUDO FDUFLQRJHQHVLV LQWHUIHUHV ZLWK WKH S SDWKZD\ DQG WKDW WKLV VHHPV WR RFFXUϱϬ
LQGHSHQGHQWO\RIWKHSUHVHQFHRIPXWDWLRQVϱϭ
ϱϮ
ϱϯ
ϱϰ
ϱϱ
ϱϲ
ϱϳ
 ϱϴ
ϯ,1752'8&7,21ϱϵ
$SSUR[LPDWHO\RIDOOFDQFHUFDVHVDUHDWWULEXWDEOHWRLQIHFWLRXVDJHQWVZLWK(SVWHLQϲϬ
%DUUYLUXV(%9EHLQJRQHRIWKHPRVWLPSRUWDQW>@(%9LVDXELTXLWRXVSDWKRJHQWKDWϲϭ
LVKDUERUHGE\DSSUR[LPDWHO\RIDOODGXOWVWKURXJKRXWWKHZRUOGDOWKRXJKWKHLQIHFWLRQϲϮ
LV DV\PSWRPDWLF LQ WKH PDMRULW\ RI OLIHORQJ FDUULHUV >@ %DVHG RQ LWV UROH LQ WKHϲϯ
GHYHORSPHQWRIPDOLJQDQWGLVRUGHUV(%9KDVEHHQFODVVLILHGDVDJURXSFDUFLQRJHQE\ϲϰ
WKH International Agency for Research on Cancer ,$5& DQG KDV EHHQ UHODWHG ZLWKϲϱ
PDOLJQDQFLHV RI ERWK O\PSKRLG DQG HSLWKHOLDO FHOO RULJLQ > @'HVSLWHPRUH IUHTXHQWO\ϲϲ
DVVRFLDWHG ZLWK O\PSKRLG WXPRUV (%9 KDV EHHQ FRQVLVWHQWO\ IRXQG LQ WXPRU FHOOV RIϲϳ
1DVRSKDU\QJHDO&DUFLQRPD 13& FDVHV IURP HQGHPLF UHJLRQV >@ DQGPRUH UHFHQWO\ LWϲϴ
ZDVDVVRFLDWHGZLWK*DVWULF&DQFHU*&ZKHUH(%9LQIHFWLRQKDVEHHQGHWHFWHGLQDURXQGϲϵ
RIDOOFDVHV>@ϳϬ
TP53 WKH JHQH HQFRGLQJ IRU WKH WXPRU VXSSUHVVRU SURWHLQ S LV WKH PRVW IUHTXHQWO\ϳϭ
PXWDWHGJHQH LQKXPDQ FDQFHU >@'\VUHJXODWLRQRI WKH73SDWKZD\ LQYROYHGLIIHUHQWϳϮ
PHFKDQLVPV WKDW LQFOXGH JHQHWLF DOWHUDWLRQV LQDFWLYDWLRQ E\ ELQGLQJ WR YLUDO RU FHOOXODUϳϯ
RQFRSURWHLQV DQG VHTXHVWUDWLRQ RI WKH SURWHLQ LQ WKH F\WRSODVP >@ 7KH IUHTXHQF\ LQϳϰ
VRPDWLFTP53PXWDWLRQVLVKLJKO\YDULDEOHUDQJLQJIURPDURXQGLQVTXDPRXVFHOOOXQJϳϱ
FDUFLQRPDWRRQO\LQWHVWLFXODUDQGFHUYLFDOFDQFHU>@9LUDODQGEDFWHULDOLQIHFWLRQVϳϲ
VWURQJO\ PRGXODWH TP53 PXWDWLRQ IUHTXHQF\ GXH WR LWV FDSDELOLW\ RI LQWHUIHUH ZLWK Sϳϳ
DFWLYLW\ >@ )RU H[DPSOH WKH SDSLOORPDYLUXV ( SURWHLQ LQWHUDFWV GLUHFWO\ ZLWK S WRϳϴ
SURPRWH LWV GHJUDGDWLRQ >@ WKH KHSDWLWLV % YLUXV ; SURWHLQ LQKLELWV WKH QXFOHDUϳϵ
WUDQVORFDWLRQRIS>@DQG WKHDGHQRYLUXV(%SURWHLQ LQWHUDFWVGLUHFWO\ZLWKSDQGϴϬ
LQKLELWVLWVDFHW\ODWLRQ>@7KXV WKHPRGXODWLRQRISIXQFWLRQLVFOHDUO\DGYDQWDJHRXVϴϭ
IRUPDQ\YLUXVHV>@ϴϮ
(%9DVVRFLDWHGHSLWKHOLDOPDOLJQDQFLHVDUHFKDUDFWHUL]HGE\UDUHTP53PXWDWLRQV>@ϴϯ
,Q13&PXWDWLRQVRITP53DUHDUDUHHYHQWRFFXUULQJLQOHVVWKDQRIDOOFDVHV>@ϴϰ
,Q*&73SDWKZD\G\VUHJXODWLRQLVGXHWRTP53PXWDWLRQVLQDSSUR[LPDWHO\RIDOOϴϱ
FDVHV>@QHYHUWKHOHVV LQWKH(%9DVVRFLDWHGJDVWULFFDQFHUVPXWDWLRQV LQTP53DUHϴϲ
LQIUHTXHQW>@7KHVHILQGLQJVVXJJHVWWKDWRWKHUPHFKDQLVPVGLIIHUHQWIURPPXWDWLRQVϴϳ
 ϰ
VXFK DV HSLJHQHWLF PRGXODWLRQ LQGXFHG E\ (%9 SURWHLQV FRXOG EH UHVSRQVLEOH IRU Sϴϴ
GHUHJXODWLRQ>@ϴϵ
7KHDLPRIWKLVVWXG\ZDVWRFKDUDFWHUL]HSDFFXPXODWLRQDQGTP53P51$H[SUHVVLRQLQϵϬ
(%9DVVRFLDWHGQDVRSKDU\QJHDODQGJDVWULFFDUFLQRPDVFRQWULEXWLQJIRUWKHNQRZOHGJHRIϵϭ
WKHPROHFXODUPHFKDQLVPVRITP53VLOHQFLQJLQ(%9DVVRFLDWHGPDOLJQDQFLHVϵϮ
 ϵϯ
 ϱ
68%-(&760$7(5,$/6$1'0(7+2'6ϵϰ
6WXG\SRSXODWLRQϵϱ
$ UHWURVSHFWLYH VWXG\ZDV SHUIRUPHG XVLQJ  SDWLHQWV DWWHQGHG DW 3RUWXJXHVH2QFRORJ\ϵϲ
,QVWLWXWH RI3RUWR ,323RUWR ZLWK(%9DVVRFLDWHG13& 7DEOH DQGZLWK*&ϵϳ
EHLQJ  (%9SRVLWLYH DQG  (%9QHJDWLYH 7DEOH  $OO FDVHV ZHUH KLVWRORJLFDOO\ϵϴ
FRQILUPHG E\ D SDWKRORJLVW IURP RXU LQVWLWXWLRQ DQG FDWHJRUL]HG DFFRUGLQJ WR WKH:+2ϵϵ
FODVVLILFDWLRQV\VWHPVIRUHDFKW\SHRIFDQFHUϭϬϬ
13&FDVHVZHUHUDQGRPO\VHOHFWHGIURPDFRKRUWRISDWLHQWVRIRXULQVWLWXWLRQ>@*&ϭϬϭ
FDVHVZHUHVHOHFWHGIURPDFRKRUWRISDWLHQWVGLDJQRVHGZLWK*&LQLQRXULQVWLWXWLRQϭϬϮ
XQSXEOLVKHGGDWDLQFOXGLQJ(%9SRVLWLYHFDVHVDQGPDWFKHGKLVWRORJLFDOW\SHDJHϭϬϯ
DQG VWDJH RI GLVHDVH (%9QHJDWLYH FDVHV 3RVLWLYH FDVHV ZHUH GHWHFWHG XVLQJ in situ ϭϬϰ
hybridization IRU WKH GHWHFWLRQ RI(%9HQFRGHG VPDOO51$ (%(5,6+7XPRU WLVVXHVϭϬϱ
VDPSOHV ZHUH FROOHFWHG IURP WKH LQVWLWXWLRQ DUFKLYHV DQG KLVWRORJLFDO VHFWLRQV IURPϭϬϲ
IRUPDOLQIL[HG SDUDIILQHPEHGGHG ))3( WLVVXH EORFNV ZHUH XVHG IRUϭϬϳ
LPPXQRKLVWRFKHPLVWU\DQGIRU51$H[WUDFWLRQϭϬϴ
7KLVVWXG\GLGQRWLQWHUIHUHZLWKFOLQLFDOGHFLVLRQV&OLQLFRSDWKRORJLFDOGDWDZDVFROOHFWHGϭϬϵ
IURP LQGLYLGXDO FOLQLFDO UHFRUGV DQG LQVHUWHG RQ D GDWDEDVHZLWK XQLTXH FRGLILFDWLRQ$OOϭϭϬ
SURFHGXUHVZHUHDSSURYHGE\WKHHWKLFDOFRPPLWWHHRI,323RUWR&(6,32ϭϭϭ
ϭϭϮ
SDFFXPXODWLRQϭϭϯ
,+&ZDV XVHG WR LQYHVWLJDWH WKH DFFXPXODWLRQ RI S SURWHLQ XVLQJ ȝP VHFWLRQV IURPϭϭϰ
))3(WLVVXHEORFNVZLWKWKHPRQRFORQDODQWLERG\'2'$.2*ORVWUXS'HQPDUNϭϭϱ
7LVVXH VDPSOHV ZHUH VXEPLWWHG WR GHSDUDIILQL]DWLRQUHK\GUDWLRQ XVLQJ WKH IROORZLQJϭϭϲ
VHTXHQFH[\OHQHIRU[PLQXWHVYYHWKDQROIRU[PLQXWHVYYHWKDQROϭϭϳ
IRU[PLQXWHVYYHWKDQROIRUPLQXWHVDQGZDWHUIRUPLQXWHV$IWHUWKDWDQWLJHQϭϭϴ
UHWULHYDO ZDV SHUIRUPHG XVLQJ D KHDW LQGXFHG HSLWRSH UHWULHYDOPHWKRG ZKHUH WKH VOLGHVϭϭϵ
ZHUHVXEPHUVHGLQDFLWUDWHEDVHGDQWLJHQXQPDVNLQJVROXWLRQ9(&725%XUOLQJDPH&$ϭϮϬ
86$DQGKHDWHGLQWKHPLFURZDYHIRUPLQXWHVDWPHGLXPSRZHU6OLGHVZHUHDOORZHGϭϮϭ
WRFROGGRZQWRURRPWHPSHUDWXUHULQVHGLQWKHXQPDVNLQJVROXWLRQIRUDOPRVWPLQXWHVϭϮϮ
 ϲ
7KHQVDPSOHVZHUHZDVKHG LQSKRVSKDWHEXIIHUHGVDOLQH3%6FRQWDLQLQJ7ZHHQϭϮϯ
 3%67 DQG WKH HQGRJHQRXV SHUR[LGDVH ZDV EORFNHG ZLWK  K\GURJHQ SHUR[LGHϭϮϰ
+2IRUPLQXWHV6XEVHTXHQWO\WKHVOLGHVZHUHZDVKHG[LQ3%67IRUPLQXWHVϭϮϱ
WUHDWHG ZLWK 89EORFN VROXWLRQ IURPUltraVision Large Volume Detection System Anti-ϭϮϲ
Polyvalent, HRP 7+(502 6&,(17,),& )UHPRQW 86$ IRU  PLQXWHV WR EORFNϭϮϳ
QRQVSHFLILFSURWHLQELQGLQJDQGLQFXEDWHGRYHUQLJKWDW&ZLWK'2PRXVHDQWLKXPDQϭϮϴ
S PRQRFORQDO DQWLERG\ GLOXWHG  '$.2 *ORVWUXS 'HQPDUN 6OLGHV ZHUH WKHQϭϮϵ
ULQVHG LQ 3%67 LQFXEDWHGZLWKBiotinylated Goat Anti-Polyvalent Antibody 7+(502ϭϯϬ
6&,(17,),& )UHPRQW86$ LQ D KXPLG FKDPEHU DW URRP WHPSHUDWXUH IRU PLQXWHVϭϯϭ
ZDVKHG [ ZLWK 3%67 IRU  PLQXWHV DQG LQFXEDWHG ZLWK Streptavidin PeroxidaseϭϯϮ
7+(5026&,(17,),&)UHPRQW86$ IRUPLQXWHVDW URRP WHPSHUDWXUH'HWHFWLRQϭϯϯ
RI K\EULGV ZDV DFKLHYHG E\ DQ HQ]\PDWLF UHDFWLRQ XVLQJ 
GLDPLQREHQ]LGLQH '$%ϭϯϰ
ImmPACTTM DAB 9(&725 %XUOLQJDPH &$ 86$ GLOXWHG DW  DQG LQFXEDWHGϭϯϱ
GXULQJPLQXWHVDWURRPWHPSHUDWXUH7KHILQDOZDVKZDVSHUIRUPHGZLWKGLVWLOOHGZDWHUϭϯϲ
IRU PLQXWHVMayers hemalum solution 0LOOLSRUH 'DUPVWDGW *HUPDQ\ ZDV XVHG DVϭϯϳ
FRXQWHUVWDLQ$IWHUFRORUDWLRQVOLGHVZHUHZDVKHGLQUXQQLQJZDWHUIRUPLQXWHVDQGWKHϭϯϴ
IROORZLQJ VWHS ZDV VHTXHQWLDO GHK\GUDWLRQ LQ  YY HWKDQRO IRU  PLQXWHV  YYϭϯϵ
HWKDQROIRU[PLQXWHVYYHWKDQROIRU[PLQXWHVDQG[\OHQHIRU[PLQXWHVϭϰϬ
0RXQWLQJZDVSHUIRUPHGZLWK0LFURVFRS\(QWHOODQ0(5&.'DUPVWDGW*HUPDQ\ϭϰϭ
1XFOHDU S DFFXPXODWLRQ ZDV GHILQHG DV QHJDWLYH  FHOO RU SRVLWLYH ! FHOOVϭϰϮ
7XPRUV ZLWK SRVLWLYH S VWDLQLQJ ZHUH VHPLTXDQWLWDWLYHO\ FDWHJRUL]HG LQWR IRXUϭϰϯ
FDWHJRULHVDQG!RIQXFOHLVWDLQLQJSRVLWLYHϭϰϰ
ϭϰϱ
TP53P51$H[SUHVVLRQϭϰϲ
51$ ZDV H[WUDFWHG IURP ȝP VHFWLRQV XVLQJ WKH Absolutely RNA FFPE Kit $JLOHQWϭϰϳ
7HFKQRORJLHV 6DQ 'LHJR &$ 86$ DQG TXDQWLILHG XVLQJ WKH NanoDrop 1000 ϭϰϴ
Spectrophotometer v3.77KHUPR6FLHQWLILF:LOPLQJWRQ'(86$ϭϰϵ
TP53 DQG*$3'+ZHUH DQDO\]HGE\ WZRVWHS UHDOWLPH3&5XVLQJKVBPDQGϭϱϬ
KVBJTaqMan Gene Expression Assays$SSOLHG%LRV\VWHPV)RVWHU&$86$ϭϱϭ
UHVSHFWLYHO\ 5HYHUVH WUDQVFULSWDVH UHDFWLRQV ZLWK  ȝ/ ILQDO YROXPH ZHUH SHUIRUPHGϭϱϮ
 ϳ
XVLQJHigh-Capacity cDNA Reverse Transcription Kit31$SSOLHG%LRV\VWHPVϭϱϯ
)RVWHU&$86$DFFRUGLQJWRWKHPDQXIDFWXUHU
VLQVWUXFWLRQV7KHDPSOLILFDWLRQFRQGLWLRQVϭϱϰ
ZHUH DV IROORZV DQQHDOLQJ DW & IRU  PLQ H[WHQVLRQ DW & IRU  PLQ DQG 57ϭϱϱ
LQDFWLYDWLRQ DW & IRU  PLQ $OO UHYHUVH WUDQVFULSWDVH UHDFWLRQV LQFOXGHG QRWHPSODWHϭϱϲ
FRQWUROVϭϱϳ
T3&5VZHUH SHUIRUPHG LQ GXSOLFDWHV LQ LQGHSHQGHQW UHDFWLRQV ZLWK D ȝO ILQDO YROXPHϭϱϴ
PL[WXUH FRQWDLQLQJ ; RI TaqMan® Universal PCR Master Mix $SSOLHG %LRV\VWHPVϭϱϵ
)RVWHU&LW\&DOLIRUQLD86$;51$$VVD\$SSOLHG%LRV\VWHPV)RVWHU&LW\&DOLIRUQLDϭϲϬ
86$DQGQJRIF'1$57SURGXFW$PSOLILFDWLRQZDVUXQLQApplied Biosystems ϭϲϭ
Step-One Real Time PCR System $SSOLHG %LRV\VWHPV )RVWHU &$ 86$ ZLWK WKHϭϲϮ
IROORZLQJ WKHUPDOF\FOLQJFRQGLWLRQVPLQDW&IROORZHGE\F\FOHVRIVHFDWϭϲϯ
&DQGPLQDW&ϭϲϰ
7KH UHODWLYH TXDQWLILFDWLRQ RI S H[SUHVVLRQZDV DQDO\]HG XVLQJ WKH ǻǻ&WPHWKRG DOVRϭϲϱ
NQRZQ DV/LYDNPHWKRG ,Q WKLVPHWKRG&W IURP WKH WDUJHW51$ S LQ ERWK WHVW DQGϭϲϲ
FRQWUROFDVHVZHUHDGMXVWHGLQUHODWLRQWRWKH&WRIDQRUPDOL]HU51$*$3'+UHVXOWLQJϭϲϳ
LQ ǻ&W )RU WKH FRPSDULVRQ EHWZHHQ (%9D*& DQG (%9Q*&ZH KDYH FDOFXODWHG ǻǻ&Wϭϲϴ
YDOXHZKLFKDOORZVXVWRGHWHUPLQHWKHGLIIHUHQFHVLQSH[SUHVVLRQϭϲϵ
ϭϳϬ
6WDWLVWLFDO$QDO\VLVϭϳϭ
5HVXOWV ZHUH DQDO\]HG XVLQJ WKH FRPSXWHU VRIWZDUH IBM SPSS Statistics for Windows, ϭϳϮ
Version 22.0 ,%0 &RUS $UPRQN 1< 86$ 'DWD IURP DOO FDVHV ZHUH FRPSDUHG E\ϭϳϯ
6WXGHQW¶VWWHVWDQG$129$FRQVLGHULQJDVWDWLVWLFDOVLJQLILFDQFHRIpϭϳϰ
ϭϳϱ
 ϭϳϲ
 ϴ
5(68/76ϭϳϳ
SDFFXPXODWLRQϭϳϴ
7KHUHVXOWVIURP,+&DQDO\VLVDUHVKRZQLQ)LJXUHZKHUHLVGHVFULEHIRUHDFKJURXSWKHϭϳϵ
SHUFHQWDJH RI FHOOV ZLWK S DFFXPXODWLRQ )LJXUH  LOOXVWUDWHV H[DPSOHV RI SϭϴϬ
DFFXPXODWLRQLQWKHGLIIHUHQWJURXSVϭϴϭ
$OOFDVHVLQFOXGHGLQWKLVVWXG\H[FHSWRQH*&FDVHZHUHSRVLWLYHIRUWKHSUHVHQFHRISϭϴϮ
DFFXPXODWLRQ E\ LPPXQRKLVWRFKHPLVWU\ 13& FDVHV DUH D KRPRJHQHRXV JURXS ZLWK DOOϭϴϯ
VDPSOHVKDYLQJPRUHWKDQKDOIRIFHOOVZLWKSDFFXPXODWLRQFDVHVVKRZHGϭϴϰ
RIFHOOVZLWKSDFFXPXODWLRQDQG SUHVHQWHGPRUH WKDQRIFHOOVZLWKϭϴϱ
SDFFXPXODWLRQ,Q(%9Q*&FDVHVSZDVIUHTXHQWO\IRXQGZLWKϭϴϲ
DQG  RI FDVHV IRXQG ZLWK    DQG ! RI DFFXPXODWLRQϭϴϳ
UHVSHFWLYHO\6LPLODUO\WR13&(%9D*&VKRZHGDVWURQJSDFFXPXODWLRQZLWKϭϴϴ
RIFDVHVKDYLQJPRUH WKDQRIFHOOVZLWKSDFFXPXODWLRQZLWKDQGϭϴϵ
RQO\KDYLQJOHVVWKDQRIFHOOZLWKSDFFXPXODWLRQϭϵϬ
5HVXOWVVKRZHGWKDWSDFFXPXODWLRQLQ13&DQG(%9D*&LVQRWVLJQLILFDQWO\GLIIHUHQWϭϵϭ
p  ZKLOH WKHUH LV D VWDWLVWLFDOO\ VLJQLILFDQW GLIIHUHQFH EHWZHHQ (%9D*& DQGϭϵϮ
(%9Q*& p  5HJDUGOHVV RI (%9 VWDWXV WKH DQDO\VLV RI DOO JDVWULF FDQFHU FDVHVϭϵϯ
UHYHDOHGWKDWWKHUHLVQRVWDWLVWLFDOGLIIHUHQFHVEHWZHHQWKHKLVWRORJLFDOVXEW\SHVLQWKHSϭϵϰ
DFFXPXODWLRQLQWLVVXHp GDWDQRWVKRZQ6LPLODUO\WKHFRPSDULVRQRIDOOJDVWULFϭϵϱ
FDQFHU FDVHV DFFRUGLQJ WR WXPRU ORFDOL]DWLRQ DQG LQYDVLRQ SDWWHUQ LQGLFDWHG QR VWDWLVWLFDOϭϵϲ
GLIIHUHQFHVLQWKHH[SUHVVLRQRISp DQGp UHVSHFWLYHO\GDWDQRWVKRZQϭϵϳ
ϭϵϴ
TP53P51$H[SUHVVLRQϭϵϵ
7KHUHVXOWVIURPT3&5DQDO\VLVDUHVKRZQLQ7DEOHTP53P51$DQG*$3'+P51$ϮϬϬ
UHIHUHQFHJHQHZHUHHYDOXDWHGIRUDOOFDVHVDQG13&DQG(%9Q*&ZHUHH[FOXGHGϮϬϭ
RIWKHDQDO\VLVEHFDXVHTP53P51$H[SUHVVLRQZDVQRWGHWHFWHGϮϬϮ
7KH DQDO\VLV RI 13& FDVHV UHYHDOHG WKH SUHVHQFH RI TP53 P51$ ± )LJXUH  :KHQϮϬϯ
DQDO\VLQJ WKH H[SUHVVLRQ RI TP53 LQ (%9D*& ZH REVHUYHG D VLJQLILFDQW GHFUHDVH ϮϬϰ
ǻǻ&W p LQTP53P51$H[SUHVVLRQLQFRPSDULVRQZLWK(%9Q*&±)LJXUHϮϬϱ
 ϵ
)XUWKHU DQDO\VLV VXEGLYLGLQJ (%9Q*& DFFRUGLQJ WR KLVWRORJLFDO VXEW\SHV UHYHDOHG WKDWϮϬϲ
(%9D*& TP53 P51$ H[SUHVVLRQ ZDV VLJQLILFDQWO\ GHFUHDVHG ZKHQ FRPSDUHG ZLWKϮϬϳ
(%9Q*& SRRUO\ FRKHVLYH DQG (%9Q*& WXEXODU KLVWRORJLFDO VXEW\SHV ǻǻ&W ϮϬϴ
p DQG ǻǻ&W  p  UHVSHFWLYHO\ GHVSLWH QRW VWDWLVWLFDOO\ VLJQLILFDQW WKHϮϬϵ
UHGXFWLRQ RI H[SUHVVLRQ DOVR RFFXUV ZKHQ FRPSDULQJ ZLWK (%9Q*& PL[HG W\SHV ϮϭϬ
ǻǻ&W p )LJXUHϮϭϭ
0RUHRYHU WKHFRPSDULVRQRITP53P51$H[SUHVVLRQEHWZHHQ*&KLVWRORJLFDOVXEW\SHVϮϭϮ
UHJDUGOHVVRI(%9VWDWXVUHYHDOHGDGLIIHUHQFHZLWKVWDWLVWLFDOVLJQLILFDQFHEHWZHHQPL[HGϮϭϯ
DGHQRFDUFLQRPDVDQGSRRUO\FRKHVLYHFDUFLQRPDVǻǻ&W p  ,QDGGLWLRQ WKHϮϭϰ
DQDO\VLV RI *& FDVHV DFFRUGLQJ WR WXPRU ORFDOL]DWLRQ DQG LQYDVLRQ SDWWHUQ LQGLFDWHG QRϮϭϱ
VWDWLVWLFDOVLJQLILFDQWGLIIHUHQFHVLQTP53P51$H[SUHVVLRQϮϭϲ
Ϯϭϳ
Ϯϭϴ
Ϯϭϵ
ϮϮϬ
 ϮϮϭ
 ϭϬ
',6&866,21ϮϮϮ
'HVSLWHWKHJUHDWQXPEHURIJHQHVLQYROYHGLQKXPDQFDUFLQRJHQHVLVTP53JHQHKDVEHHQϮϮϯ
FRQVLGHUHGDVRQHRIWKHPRVWLPSRUWDQWJHQHVEHLQJFUXFLDOLQWKHUHJXODWLRQRIVLJQDOOLQJϮϮϰ
SURFHVVHV RI WXPRU GHYHORSPHQW >@ 7KH S SURWHLQ LV DFWLYDWHG LQ UHVSRQVH WRϮϮϱ
HQGRJHQRXVRU H[RJHQRXV VWUHVVHV LQGXFLQJ FHOO F\FOH DUUHVW'1$ UHSDLU DSRSWRVLV DQGϮϮϲ
VHQHVFHQFHRIFHOOV>@7KHUHIRUHWKHPRGXODWLRQRITP53 LVFRQVLGHUHGDNH\KDOOPDUNϮϮϳ
IRU FDQFHU GHYHORSPHQW DQG WKHUH DUH VHYHUDO PHFKDQLVPV WKDW FRQWULEXWH IRU LWVϮϮϴ
GHUHJXODWLRQ>@TP53JHQHPXWDWLRQVDUHRQHRIWKHPRVWIUHTXHQWDOWHUDWLRQVLQKXPDQϮϮϵ
FDQFHUV RFFXUULQJ LQ DOPRVW HYHU\ W\SH RI FDQFHU DW UDWH RI  WR  > @ϮϯϬ
)XUWKHUPRUH YLUXVHV KDYH EHHQ FRQVLGHUHG DV DEOH WR PRGXODWH S SDWKZD\ HLWKHU E\Ϯϯϭ
GLUHFWLQDFWLYDWLRQRIWKHSURWHLQRUE\JHQHJHQHLQWHUDFWLRQ>@ϮϯϮ
(%9 KDV EHHQ GHVFULEHG LQ WKH SDWKRJHQHVLV RI O\PSKRSUROLIHUDWLYH GLVRUGHUV DVZHOO DVϮϯϯ
HSLWKHOLDOPDOLJQDQFLHVVXFKDV13&DQG*&>@2QHRIWKHSRWHQWLDOWDUJHWVRI(%9Ϯϯϰ
LQFDUFLQRJHQHVLVSURFHVVHV LV WKHSSDWKZD\DQGSUHYLRXV VWXGLHVKDYHVKRZQ WKDW WKHϮϯϱ
IUHTXHQF\RITP53 JHQHPXWDWLRQVLQ(%9DVVRFLDWHGPDOLJQDQFLHVLVORZ>@,QIDFWϮϯϲ
VRPHVWXGLHVKDYHVKRZQWKDWLQ13&DQG(%9D*&TP53LVUDUHO\PXWDWHGVXJJHVWLQJWKDWϮϯϳ
RWKHUPHFKDQLVPVGLIIHUHQWIURPPXWDWLRQVFRXOGEHUHVSRQVLEOHIRUSGHUHJXODWLRQ>Ϯϯϴ
@ 8QGHUVWDQGLQJ WKH PHFKDQLVPV RI (%9DVVRFLDWHG S GHUHJXODWLRQ LQ WKHVHϮϯϵ
FDQFHUVZRXOGDOORZDEHWWHUNQRZOHGJHRIWKHFDUFLQRJHQHVLVPRGHOLQHSLWKHOLDOWXPRUVϮϰϬ
&RQFHUQLQJ13&ZHKDYHIRXQGSDFFXPXODWLRQLQRIFDVHVDQGDOOVKRZHGPRUHϮϰϭ
WKDQ  RI FHOOV ZLWK S DFFXPXODWLRQ 3UHYLRXV VWXGLHV DOVR VKRZHG D KLJK SϮϰϮ
DFFXPXODWLRQ UDQJLQJ EHWZHHQ  DQG  > @ 7KH UHODWLRQVKLS EHWZHHQϮϰϯ
DFFXPXODWLRQRISLQ13&DQG(%9LQIHFWLRQLVVWLOOFRQWURYHUVLDO>@$OWKRXJKϮϰϰ
WKH PHFKDQLVP E\ ZKLFK (%9 LQGXFHG S H[SUHVVLRQ KDV QRW EHHQ HOXFLGDWHG VRPHϮϰϱ
DXWKRUVVXJJHVWHG WKDW/03DKLJKO\H[SUHVVHG(%9ODWHQWSURWHLQ LQ13&VHHPWREHϮϰϲ
UHVSRQVLEOHIRUSDFFXPXODWLRQLQ13&ZLWKRXW73JHQHPXWDWLRQ>@,QGHHG/03Ϯϰϳ
VHHPV WR LQGXFH ZLOGW\SH S VWDELOL]DWLRQ WKURXJK WKH SURPRWLRQ RI .OLQNHGϮϰϴ
XELTXLWLQDWLRQZKLFKLVDFHOOXODUSDWKZD\UHJXODWRUDQGWKXVHQKDQFLQJWKHKDOIOLIHRIWKHϮϰϵ
SURWHLQ > @ )XUWKHUPRUH /03 DOVR EORFNV 0'0PHGLDWHG S GHJUDGDWLRQϮϱϬ
 ϭϭ
WKURXJK WKHVXSSUHVVLRQRI.OLQNHGXELTXLWLQDWLRQ >@7RJHWKHU WKLVGXDO IXQFWLRQRIϮϱϭ
/03H[SODLQVWKHZLOGW\SHSDFFXPXODWLRQLQ13&WLVVXH>@ϮϱϮ
5HJDUGLQJ S DFFXPXODWLRQ LQ *& RXU VWXG\ UHYHDOHG DQ RYHUDOO KLJK UDWH RI SϮϱϯ
DFFXPXODWLRQLQ(%9D*&DQGLQ(%9Q*&6LPLODUUHVXOWVZHUHIRXQGE\Ϯϱϰ
RWKHUDXWKRUVWang et al.UHSRUWHGDKLJKSDFFXPXODWLRQLQERWK(%9D*&DQGϮϱϱ
(%9Q*&>@DQGKim et al.VKRZHGPRUHSDFFXPXODWLRQLQ(%9D*&Ϯϱϲ
FRPSDUHG WR (%9Q*&  DQG ZLWK D SUHGRPLQDQFH RI !  RI FHOOV ZLWK SϮϱϳ
DFFXPXODWLRQLQERWK(%9D*&DQG(%9Q*&>@2WKHUVWXGLHVVKRZHGϮϱϴ
FRQWUDGLFWRU\ UHVXOWV UHSRUWLQJ OHVVSDFFXPXODWLRQ LQ(%9D*&FRPSDUHG WR(%9Q*&Ϯϱϵ
>@ DQG RQH PHWDDQDO\VLV VWXG\ GHPRQVWUDWHG D ORZHU UDWH RI S DFFXPXODWLRQϮϲϬ
DOWKRXJKQRWVWDWLVWLFDOVLJQLILFDQWLQ(%9D*&ZKHQFRPSDUHGZLWKLQ(%9Q*&Ϯϲϭ
 >@ 2XU UHVXOWV VHHP WR VXJJHVW WKDW DFFXPXODWLRQ RI S LQ JDVWULF FDQFHU LVϮϲϮ
LQGHSHQGHQWRI(%9LQIHFWLRQ>@Ϯϲϯ
,QRXUVWXG\ WKHGHWHFWLRQRISDFFXPXODWLRQZDVSHUIRUPHGE\,+&IRUSXVLQJWKHϮϲϰ
'2 DQWLERG\ WKDW UHFRJQL]HV ERWKZLOGW\SH DQGPXWDQW IRUPV RI S >@ 7KLV LV DϮϲϱ
FKHDSDQGUDSLGPHWKRGZLGHO\XVHGLQURXWLQHSURFHGXUHVEHLQJWKHFRPPRQHVWPHWKRGWRϮϲϲ
LQIHUTP53 PXWDWLRQDO VWDWXV LQ RYDULDQ FDUFLQRPD >@ VLQFH LW LV PRUH OLNHO\ WR GHWHFWϮϲϳ
PXWDWHGSGXHWRLWVORQJHUKDOIOLIHXVXDOO\SFRQVLGHULQJWKDWDFFXPXODWLRQLVUHODWHGϮϲϴ
WRTP53JHQHPXWDWLRQ>@+RZHYHULQWKHPDMRULW\RIVWXGLHVWKDWKDYHXVHG,+&DVDϮϲϵ
VXUURJDWHPDUNHUIRU73PXWDWLRQKDYHIDLOHGWRGHPRQVWUDWHFRQVLVWHQWUHVXOWV>@E\ϮϳϬ
VKRZLQJDODUJHQXPEHURIPLVFODVVLILHGFDVHVIDOVHSRVLWLYHDQGIDOVHQHJDWLYH>@,QRXUϮϳϭ
VWXG\ S VWDLQLQJ ZDV QXFOHDU LQ WXPRU FHOOV DQG ZDV DEVHQW LQ QRUPDO FHOOV DQGϮϳϮ
FRQVLGHULQJWKDWLQ(%9D*&DQG13&TP53PXWDWLRQVDUHUDUH>@LWLVϮϳϯ
GLIILFXOWWRUHFRQFLOHZLWKWKHREVHUYDWLRQRISDFFXPXODWLRQϮϳϰ
,QRUGHU WREHWWHUXQGHUVWDQG LI WKHDFFXPXODWLRQRISZDV DFRQVHTXHQFHRI LQFUHDVHGϮϳϱ
TP53WUDQVFULSWLRQZHKDYHDOVRLQYHVWLJDWHGWKHTP53P51$E\T573&5$VIDUDVZHϮϳϲ
NQRZ WKLV LV WKH ILUVW VWXG\XVLQJT573&5PHWKRGRORJ\ WRHYDOXDWH WKH OHYHOVRITP53Ϯϳϳ
JHQHH[SUHVVLRQLQ(%9D*&Ϯϳϴ
$PRQJ *& ZH IRXQG D VLJQLILFDQW GHFUHDVH LQ TP53 P51$ H[SUHVVLRQ LQ (%9D*&Ϯϳϵ
ZKLFKKDGOHVVRITP53P51$H[SUHVVLRQZKHQFRPSDUHGZLWK(%9Q*&$IXUWKHUϮϴϬ
 ϭϮ
VXEGLYLVLRQ RI(%9Q*& LQ GLIIHUHQW KLVWRORJLFDO VXEJURXSV VKRZHG WKDW(%9D*&KDG DϮϴϭ
VLJQLILFDQW GRZQUHJXODWLRQ RI TP53 P51$ H[SUHVVLRQ LQGHSHQGHQW RI KLVWRORJLFDOϮϴϮ
VXEW\SHV7KLV UHVXOW FRXOGEHH[SODLQHGE\ WKHSRWHQWLDORI VRPH(%9 ODWHQWSURWHLQV WRϮϴϯ
GHVWDELOL]HS(%1$KDVEHHQGHVFULEHGWRFRPSHWHZLWKSIRUWKHVDPHELQGLQJVLWHϮϴϰ
RI863DFHOOXODUXELTXLWLQVSHFLILFSURWHDVHWKDWKDVEHHQUHSRUWHGWRELQGDQGUHJXODWHϮϴϱ
S DQG LWV KLJKHU DIILQLW\ LQWHUIHUHVZLWK WKH VWDELOL]DWLRQRI S FRQWULEXWLQJ IRU ORZHUϮϴϲ
S OHYHOV >@ (%1$& UHSRUWHG DV FDSDEOH WR GLUHFWO\ ELQG S DQG UHSUHVV LWVϮϴϳ
DSRSWRWLFDQG WUDQVFULSWLRQDODFWLYLWLHV >@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Figure 1. Percentage of cells with p53 accumulation in nasopharyngeal and gastric carcinomas. 
 
NPC, Nasopharyngeal carcinoma; EBVaGC, Epstein-Barr Virus-associated Gastric Carcinomas; EBVnGC, Epstein-Barr 
Virus-negative Gastric Carcinomas. 
Figure 2. Examples of immunohistochemistry staining on nasopharyngeal and gastric carcinomas.  
EBER-ISH (40x): A) NPC; B) EBVaGC; C)EBVnGC.  
p53 (40x): D) NPC; E) EBVaGC; F) EBVnGC. 
 
NPC, Nasopharyngeal carcinoma; EBVaGC, Epstein-Barr Virus-associated Gastric Carcinomas; EBVnGC, Epstein-Barr 
Virus-negative Gastric Carcinomas. 
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Figure 3. Expression profile of TP53 mRNA in nasopharyngeal and gastric carcinomas.  
 
NPC, Nasopharyngeal carcinoma; EBVaGC, Epstein-Barr Virus-associated Gastric Carcinomas; EBVnGC, Epstein-Barr 
Virus-negative Gastric Carcinomas. Bold values are statistically significant different. 
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ABSTRACT (max 150-250words) 
Our study aimed to summarize, with a systematic review of literature, Epstein-Barr Virus 
(EBV) gene expression patterns in gastric carcinomas  (GC). A systematic search of 
literature regarding the expression of EBV proteins and EBV latency pattern in gastric 
carcinomas was performed. The search retrieved 247 papers, of which 25 papers matched 
the inclusion criteria. Data regarding background characteristics of population, histologic 
information, type of sample, viral genes expression and methodologies were extracted from 
included papers. The analysis reveals that not all studies evaluate the necessary proteins 
for the characterization of latency profiles in GC. The most frequently expressed EBV latent 
proteins are EBNA1 (98.1%) and LMP2A (53.8%), while LMP1 and LMP2B are only present 
in 10% of cases. The combination of protein expression showed that the most frequent 
pattern found in GC (44.4%) does not fit to the standard viral latency patterns. Moreover, 
lytic proteins, such as BARF0 and BARF1 (100% and 63.9%, respectively), and other lytic 
transcripts are present in almost half of cases. Our review showed that EBV-associated GC 
(EBVaGC) seems to display a unique transcription pattern. More studies combining 
information regarding latent and lytic proteins may provide significant information to better 
understand EBVaGC carcinogenesis. 
Keywords: EBVaGC, EBV Latency, Lytic genes, Latent Genes
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INTRODUCTION 
Epstein-Barr Virus (EBV) is a human cancer-associated virus that infects about 90% of the 
global population, and despite its wide distribution, does not cause major symptoms in the 
majority of lifelong carriers [1-3]. Nevertheless, EBV has a great carcinogenic potential and 
has been described as the aetiological agent of several malignancies, especially B-cell 
neoplasias, but has also been associated with epithelial tumours such as Nasopharyngeal 
Carcinoma (NPC) and more recently to Gastric Carcinoma [4,1]. 
Gastric cancer (GC) is the sixth most common malignancy and the second leading cause of 
cancer death worldwide [5,6]. GC has a distinct geographic distribution suggesting that 
genetic and environmental factors play important roles on its development [7,6]. Gastric 
carcinogenesis is a multistep process, where different factors are involved and where EBV 
seems to be involved in the mechanism of some cases [5,8,9]. Literature evidences have 
shown that almost 10% of GC cases are associated to EBV infection, which lead the 
scientific community to debate the role of EBV infection on GC [10-12]. Indeed, EBV 
infection has been detected in both gastric adenocarcinomas and lymphoepithelioma-like 
carcinomas (LELC) [13,9]. The evidence for involvement of EBV in gastric carcinoma is 
based on the presence of viral gene products such as EBV-encoded small RNAs (EBER) in 
tumour cells but not in the surrounding non-neoplastic epithelium [14], the presence of clonal 
EBV in tumour cells [15] and elevated EBV antibodies in prediagnostic sera of patients with 
EBV-associated gastric carcinoma [16].  Moreover, recent studies have suggested that the 
EBV-associated gastric cancer (EBVaGC) is a distinct subgroup of gastric cancers with 
specific molecular features [17,9,18]. 
The development of EBV-associated malignancy is dependent on the expression of viral 
proteins that modulate cell proliferation, immune response and apoptosis [19,20]. Indeed, 
EBV has several latent proteins involved in this processes that are expressed in different 
conditions in EBV-associated malignancies [21,22]. There are different patterns of viral latent 
gene expression: Latency I, present in Burkitts lymphoma; Latency II present in 
Nasopharyngeal carcinoma, Hodgkins disease and natural killer (NK)/T-cell lymphomas; 
and Latency III which is found in Post-transplant lymphoma and AIDS-associated non-
Hodgkins lymphoma [2].  
Regarding EBVaGC, some studies suggested that it is usually associated with latency I 
pattern, although, controversial reports suggest different latency patterns of viral gene 
expression [23-25]. The clarification of which both lytic and latent EBV genes are expressed 
in GC assumes a great importance for the development of future studies regarding EBV- 
associated carcinogenesis in gastric cells. The aim of this study was to summarize EBV 
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gene expression patterns in gastric carcinomas by performing a systematic review of 
literature.  
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MATERIAL AND METHODS 
Articles search  
In this systematic review we revised all published studies regarding the expression of EBV 
proteins in gastric carcinomas. A systematic PubMed/Medline and EMBASE search was 
performed to identify all published reports from January 1980 to December 2015 using the 
following query: ebv[All Fields] OR ("herpesvirus 4, human"[MeSH Terms] OR human 
herpesvirus 4"[All Fields] OR ("epstein"[All Fields] AND "barr"[All Fields] AND "virus"[All 
Fields]) OR "epstein barr virus"[All Fields]) AND ("stomach"[MeSH Terms] OR "stomach"[All 
Fields] OR "gastric"[All Fields]) AND ("latent"[All Fields] OR "Lytic"[All Fields] OR 
("micrornas"[MeSH Terms] OR "micrornas"[All Fields] OR "mirna"[All Fields]) OR (ebv[All 
Fields] AND latency[All Fields])). Furthermore, a hand search of abstract books from 
scientific meetings and the reference list of review manuscripts was also performed. 
Inclusion and exclusion criteria 
All studies performed to evaluate the expression of EBV proteins and EBV latency patterns 
in gastric carcinomas were evaluated. Articles were excluded if they met one or more of the 
following criteria: 1) reviews, meta-analysis, or systematic reviews; 2) not related with gastric 
cancer; 3) in vitro studies; and 4) studies with methods and results not available in English, 
Portuguese, Spanish or French - Figure 1. 
Studies selection and data extraction  
The study selection was performed in two steps (screening and data extraction) 
independently by two authors and disagreements were solved consulting a third author. 
Firstly, the title and abstract were screened following an evaluation of relevant full-text 
studies based on the inclusion and exclusion criteria. A request via email was sent by 
authors when full-texts were not available or when results were written in other language 
than English, Portuguese, Spanish or French. All included manuscripts were revised by two 
authors, in order to extract the necessary data to perform the analysis: first author, journal 
name, year of publication, data from characterization of population (ethnicity, median age, 
country), source of sample (formalin-fixed and paraffin-embedded tissues; frozen tissues), 
number of cases, histological types of GC (when reported), expression of EBV proteins 
(each) and methodology used for the detection of protein expression (Immunochemistry, 
real-time polymerase chain reaction, in situ hybridization).  
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RESULTS
A total of 247 articles were evaluated from which only 25 were included in the final analysis. 
The motifs for exclusion were: 56 reviews articles, 58 in vitro studies, 54 did not evaluate the 
expression of EBV proteins, 41 were not related to gastric cancer, 5 were not available in 
either full-text or at least the results section, 4 were written in Chinese, 3 had replicated data 
from previous papers and 1 was found to be a case report  Figure 1.   
Table I describes the principal baseline characteristics of included studies, namely the 
population of study, type of samples, number of cases, proteins analysed and EBV latency 
pattern, when described by authors [26,15,27-31,23,32-39,24,40-42,25,43-47]. The majority 
of studies were performed in Asiatic populations (Japan, China, Hong Kong, Korea and 
India); three studies were from European populations (United Kingdom, France and 
Netherlands); and one study from USA and Central America. Regarding the histological 
classification of gastric carcinomas, only 16 studies provided this information. The detection 
of EBV was performed by in situ hybridization for Epstein-Barr virus-encoded RNA (EBER-
ISH) in the majority of studies, while only two studies evaluate EBV presence by Polymerase 
Chain Reaction (PCR) and one used a RNA compass technology. Studies analysed different 
viral proteins and used different approaches for the detection of the different proteins 
(Immunochemistry, reverse transcriptase PCR, within others). 
 
Expression of EBV latent infection genes 
The expression of EBV latent proteins in the cases included in studies are described in 
Table II.  As expected, the majority of included studies (n=23) have analysed at least one of 
EBV latent proteins: EBNA1 was reported in 16 studies and detected in 98.1% of all cases 
(254/259), revealing strong homogeneity amongst results; EBNA2 was analysed in 15 
studies and despite it was detected in 3.1% of cases (6/193), the positivity was observed 
only in one study with 42.9% of cases being positive (6/14); LMP1 was analysed in 18 
studies with 10.6% of cases positive (21/199), nevertheless, results showed that only four 
studies have positive cases, and in those there was a wide range of positivity (between 19-
100%); LMP2A was analysed by 12 studies and was positive in 53.8% cases (113/210) 
revealing a great heterogeneity; and LMP2B was only analysed by 3 studies with an overall 
positivity of 13.6% (3/22) explained only by one study with positive results. 
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Expression of EBV lytic infection genes 
The literature shows that in addition to the several EBV latency proteins, there are several 
authors which have identified different transcripts from EBV lytic genes:  EBV immediate-
early genes BZLF1 and BRLF1; early genes BARF1 and BHRF1; late genes BcLF1 and 
BLLF1; and some also analyse BALF5 and BXLF1. The description of results regarding the 
detection of EBV lytic gene products is described in Table III.   
The revised data showed that the expression of EBV lytic proteins is very more 
heterogeneous than latent proteins: BZLF1 was studied in 14 studies and was expressed in 
34.2% (63/184) of cases, however there is a great heterogeneity among results varying 
between 0%-92.9%; two studies investigated the presence of BARF0 and both detected 
100% positivity (14/14); BARF1 transcripts were analysed in 7 studies and were positive in 
71.0% (76/107) of cases; six studies analysed BHRF1 transcripts and only 8.02% (9/56) 
(8.02%)  were positive; BRLF1 was detected by 4 studies in a total of 56.2% (18/32), but 
with despair results among studies; 61.1% (33/54) exhibited BcLF1 as reported by two 
studies; 45 of 76 cases (59.2%), described in 6 studies, expressed BLLF1; 12 of 25 (48.0%) 
cases were positive for BMRF1; and 29 of 48 (60.4%) cases exhibited BARTs transcripts. 
BALF5, BXLF1 and BCRF1 were also detected by one study, which found BALF5 and 
BXLF1 transcripts in 14 of 14 cases and BCRF1 in 11 of 14).  
Shinozaki-Ushiku and colleagues in addiction to detect the overall expression of BARTs, 
they have used TaqMan MiRNA assays to evaluate a relative quantification of each ebv-mir, 
including microRNAs from BHRF1 region [46].  
 
EBV Latency Profiles 
As previously described, latency patterns are characterized by the expression of specific 
EBV latent proteins [2]: Latency I, characterized by expression of EBERs1/2, EBNA1 and 
BARTs; Latency II is defined by EBERs1/2, EBNA1, LMP1 and LMP2 expression; and 
Latency III is characterized by EBERs1/2, BARTs, all six EBNA proteins and LMP1 and 
LMP2 proteins.  
Overall, of the 25 included studies, 17 did not provide enough information for the 
determination of EBV latency pattern. Nevertheless, 6 studies evaluated the latent proteins 
expression despite did not describe the latency pattern, and only 2 were able to describe the 
EBV latency pattern for the cases. We have revised all data and managed to reclassify the 
latency profiles of the 8 studies with sufficient information  Table IV.  
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EBV latency I was found in 7/8 studies and representing almost 42.9% of cases; and latency 
II and III were only identified in one study. Additionally, studies identify a distinct latency 
pattern, characterized by the expression of EBERs, EBNA1, LMP2 and the absence of 
LMP1 and EBN2A, which some authors have named latency II-like [23,2]. This pattern was 
found in 44.4% of all cases being the most frequent latency pattern in EBVaGC.  
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DISCUSSION 
EBV establishes a latent infection expressing a restrict set of viral proteins that confer to the 
infected cells a survival advantage and proprieties to escape immune surveillance [48]. 
Literature suggest that EBV can adopt mainly four distinct latent infections according the 
type of cells (epithelial or lymphoid): latency 0, I, II, and III [21]. The different latency 
programs are characterized by specific viral gene expression pattern and are dependent on 
several cell-specific factors such as epigenetic events, which include DNA methylation, 
histone modifications and chromatin organization [49,50]. The profile of expression of latent 
viral proteins is crucial for the transformation of cells being the major responsible for the 
carcinogenesis [48]. The different EBV latency programs have been correlated with different 
EBV-associated diseases [48,2]. Studies have shown that in NPC, EBV is characterized by 
latency II; nevertheless in other EBV-associated epithelial malignancies it may express 
different latency patterns. 
EBV has been suggested to be associated with the development of at least part of gastric 
cancer (EBVaGC); however the impact of EBV latent and lytic genes on gastric 
carcinogenesis remains controversial and unclear [11,12]. The selective expression of EBV 
genes contributes to the malignant transformation of epithelial cells by disrupting various 
cellular processes and signalling pathways [51-53]. Indeed, the distinct mutation signature 
and methylation pattern identified in EBVaGC illustrate that EBV infection facilitates a unique 
and alternate tumorigenic process in epithelial malignancies [54,9]. Hence, this systematic 
review intends to resume the data published regarding EBV gene expression in gastric 
tumors and clarify the latency pattern that characterizes best EBVaGC in order to improve 
the knowledge on the carcinogenesis mechanism.  
By searching literature, we have found 25 papers matching the inclusion criteria and 
exploring the expression of EBV proteins in gastric cancer. Two independent authors 
performed the screening and data extraction from included papers in order to minimize 
errors. The first problem found in this systematic review was the difficulty to summarize the 
baseline characteristics of the studies due to the great heterogeneity. Indeed, the lack of 
standardization of EBV detection methodologies and the methodological limitations, 
including smaller sized samples, constitute a major limitation for this review. 
The incidence of gastric cancer is substantially higher in Asia fostering the research in this 
field among Asiatic populations, and as expected, the majority included studies were 
performed in Asiatic populations [55,15,31,32,34-36,39,24,40,44-47]. Nevertheless, there 
are other areas of the world with significant impact of GC that should promote the 
development of more studies to characterize better the impact of EBVaGC worldwide.   
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The selection of the methodology for EBV detection relies on several factors, such as the 
type of sample available, and therefore different tests may be used. The detection of EBV 
has been performed by identifying the presence of the virus in tissues samples, especially in 
paraffin embedded formalin fixed tissue (FFPE) sections. The in situ hybridization with EBV 
EBERs (EBER-ISH) has been considered the gold standard method [56] and it was chosen 
by the majority of studies included in this systematic review. Nevertheless, other methods 
with different specificities and sensitivities were also used (western-blot, PCR, RT-qPCR for 
EBNA1 and RNA CoMPASS) [15,33,35,36,42,43]. The methodologies used to EBV 
detection among gastric tissues are an important factor, which must be taken into account 
during the comparative analysis of EBV prevalence between different populations or studies.  
Other important limitation found was the impossibility to compare the expression profile 
among different histological types, which has assuming great importance. The association 
between EBV and GC was firstly reported among gastric medullary carcinomas with 
lymphoid infiltration (lymphoepitheliomas/LELC), described by World Health Organization 
(WHO) as an uncommon subtype and is not represented in the classification system most 
widely used in GC (Lauren s classification) [57]. Several authors have identified 
morphological features similar to the undifferentiated nasopharyngeal carcinoma (UNPC), 
and some refer it as gastric medullary carcinoma with lymphoid infiltration (GMCL) 
[58,26,27,39]. This tumour, which has been characterized by uniform proliferation of cancer 
cells throughout the lymphoid stroma, represents about 4% of all gastric carcinomas and 
more than 80% of all cases are associated with EBV [13]. Nevertheless, EBV has been 
detected in other histological subtypes of GC with distinct associations dependent on the 
histological type [23,9]. In this systematic review we observed that only 16 studies provide 
information regarding the histologic types, with a strong heterogeneity regarding histological 
classification applied in each study. The different classifications and definitions contribute to 
the great heterogeneity among study populations making the analysis of association 
between EBV proteins expression and gastric cancer histological types extremely difficult. 
According to the literature, there are no evidences that EBV latency pattern may vary among 
different histological types.  The summary of this information is important to overcome 
differences, specially comparing LELCs and others histological types. This limitation reflects 
the lack of information regarding gastric cancer histology in studies.  
 
EBV protein expression in Gastric Cancers 
EBV protein expression and latency patterns can be directly influenced by the method 
selected for the analysis since it may lead to different interpretations concerning if they are 
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analysing proteins and/or transcripts. The studies included in this systematic review detected 
EBV proteins including different methods including, immunochemistry (IHC), western-blot 
(WB), reverse transcriptase PCR (RT-PCR), RNA CoMPASS and arrays  Table I. While 
some methods directly identify the presence of the protein in the tissue (IHC, WB or IF), 
others detect the presence of transcripts from the genes (RT-PCR, RNA CoMPASS and 
arrays). This may lead to a misconception, since the presence of a transcript in a tissue does 
not imply the protein expression, because post-transcriptional modifications and RNA 
degradation or inhibition may occur. Nevertheless, it is not possible to point which of the 
strategies is correct. Actually, they have both advantages and disadvantages: whereas RT-
qPCR and RNA CoMPASS are considered the methods with highest sensitivity detecting low 
levels of RNA; IHC allows to detect proteins and to analyse their location in the tissues [43]. 
Considering that there are differences on the expression of EBV proteins/transcripts, the 
correct interpretation of data from studies considering the methods may help to explain 
different results between studies.  
As expected in all forms of EBV latency, EBNA1 is expressed in almost all cases (98.1%) of 
EBVaGC. In fact, this protein is a DNA binding nuclear phosphoprotein, which plays a crucial 
role in the replication and maintenance of the episomal EBV genome [59]. Some have been 
suggesting that EBNA1 also contributes to the transcription of other viral latency genes 
contributing to the carcinogenesis [60,61]. In contrast to EBNA1, the expression of EBNA2 
was not expected in gastric malignancies because EBNA2 seems to be B cell specific [62]. 
EBNA2 acts as a transcriptional coactivator factor that coordinates viral gene expression in 
latency III and also can transactivates cell genes playing a critical role in cell immortalization 
[1]. In fact, only one study have detected EBNA 2 in some cases of EBVaGC and authors 
explained that they have used a sensitive array, which found low albeit detectable levels 
[25]. Our review also shows that LMP1 is generally absent in EBVaGC except for the data 
reported in three studies, which have detected LMP1 expression in some cases of EBVaGC 
[38,25,43]. Although LMP1 protein was previously reported to be absent in EBVaGC, recent 
approaches detecting LMP1 mRNA have pointed for its presence in almost 100% of all 
specimens [25,43]. The explanation for LMP1 detection in some cases could be due to 
differences between methods sensitivities and the amount of LMP1 in the tissues. Indeed, 
two of the three studies that detected LMP1 used arrays and RNA CoMPASS 
methodologies, which detect RNA transcripts and not the protein [38,25]. Moreover, recent 
have data suggested that LMP1 may itself get silenced by methylation of its own promoter, 
explaining the lack of LMP1 expression [63]. 
EBV LMP2A was found in half of EBVaGC cases and this fact has boosted the research on 
this field, since it has been suggested that LMP2A contributes to gastric carcinogenesis by 
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inducing the genome hypermethylation through phosphorylation of STAT3 and up-regulation 
of DNMT1 [64,17].  
Our systematic review also analysed the information regarding the expression of EBV lytic 
genes in EBVaGC. Surprisingly, several lytic proteins/transcripts were found (BZLF1, BcLF1, 
BLLF1, BHRF1, BRLF1, BMRF1), including glycoproteins and proteins from the replication 
core. Nevertheless, as for latent genes, the methods used may influence the conclusions. 
The majority of studies detect mRNA and not the expressed protein (RT-PCR, arrays and 
RNA CoMPASS) requiring future studies to clarify if the activation of EBV lytic genes is 
important or not during carcinogenesis. We found curious that using RNA-based methods, 
BZFL1 transcripts were not detected by seven studies [31,23,35,38,39,24,45] while other 
seven studies revealed that it is present in up to 93% of the cases [26,32,34,36,42,25,43]. In 
addition, studies that performed IHC and IFA failed to detect BZLF1. BARF1 was also 
detected by several studies suggesting that in EBVaGC malignancies, as well as it happens 
in NPC carcinomas without LMP1 expression, BARF1 may be acting as a viral oncogene 
[23,34-36,42,25,44]. Actually, literature has revealed that in epithelial tumours BARF1 acts 
as a latent, rather than lytic gene and have shown to be oncogenic and capable of inducing 
malignant transformation [65,66]. Overall, EBV lytic transcripts have been detected in gastric 
cancer tissues suggesting that EBV lytic cycle is activated in a small portion of EBV-infected 
carcinoma cells [32,25,43]. However, there is a possibility that the presence of EBV lytic 
proteins/transcripts may be explained by the presence of a small percentage of other cells 
such as infiltrating lymphocytes in the tumor tissues and not in the malignant cells. The role 
of EBV lytic gene expression in EBVaGC remains unclear and more functional studies are 
required to understand their role on epithelial malignancies.  
Although it has not possible to make a quantitative analysis of these results, we have 
summarize the EBV proteins profile in individually cases from different studies, when it was 
described by authors in the manuscript (Supplementary Table I). The Supplementary Table I 
allows to compare the expression of different EBV proteins in cases individually. 
 
EBV latency profiles in Gastric Cancers
Some review articles have associated EBVaGCs with latency type I and II [67-69], 
nevertheless our systematic review reveals another latency pattern that has been found 
among EBVaGC cases. To clarify the latency pattern of EBVaGC cases, we have described 
the data regarding the expression of EBV proteins individually (Supplementary Table I) and 
summarized the data considering the latency profiles suggested by Young et al [21] and 
described the latency profiles in Table IV.  
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These data showed that Latency I is one the most frequent latency found in EBVaGC. In 
addition studies also revealed that, in a large number of EBVaGCs, EBV assumes a unique 
and distinct latency pattern [31,23,32,34,40].  This distinct latency pattern, also designated 
by latency II-like, is characterized by the expression of EBERs, EBNA 1 and LMP2A [23] 
differing from latency II since it does not expresses LMP1 [21]. The presence of LMP2A in 
these tumors could assume a crucial role on gastric carcinogenesis. LMP2A is a viral 
oncogene, capable to promote the transformation of epithelial cells by the induction and 
maintenance cell proliferation and decreasing apoptosis [51]. Furthermore, recent studies 
have shown that LMP2A have a strong influence on aberrant methylation of tumor-related 
genes in gastric cancer development [64,17]. 
Considering only latent proteins, the results are consistent attributing EBV latency II-like and 
I to gastric carcinomas. Only Tang et al have identified some EBVaGC cases expressing 
EBNA2 that allows to characterize these cases as latency III [25]. Authors have referred that 
the methodology used in their experiments has high sensitivity capable to detect low albeit 
detectable levels of LMP1 and EBNA2 [25].  As mentioned above, the expression of both 
LMP1 and LMP2A is heterogeneous in terms of prevalence and distribution within the 
tumors. These results point for different latency patterns among EBVaGC cases and 
reinforce the needed of more studies to define these speculative roles of LMP proteins in the 
development of EBV-associated epithelial cancers. 
 
Conclusion 
This systematic review demonstrates that EBVaGC are often associated with a distinct 
latency pattern, characterized by the expression of EBERs, EBNA1 and LMP2A. This profile 
does not really fit to the standard latency patterns and it has been named by latency II-like. 
Following latency II-like, latency I is the most frequently EBV latency pattern found among 
EBVaGCs. The clarification of the different latency patterns is important to allow directed 
strategies in future treatment options. Furthermore, some studies have shown the 
expression of EBV lytic genes in EBVaGC and therefore its role is still unclear. These data 
evidences that further studies are required to mechanisms of viral carcinogenesis in 
EBVaGC.  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
REFERENCES 
1. Thompson MP, Kurzrock R (2004) Epstein-Barr virus and cancer. Clin Cancer Res 10 
(3):803-821 
2. Young LS, Rickinson AB (2004) Epstein-Barr virus: 40 years on. Nat Rev Cancer 4 
(10):757-768. doi:nrc1452 [pii] 10.1038/nrc1452 
3. Xiong G, Zhang B, Huang MY, Zhou H, Chen LZ, Feng QS, Luo X, Lin HJ, Zeng YX 
(2014) Epstein-Barr virus (EBV) infection in Chinese children: a retrospective study of 
age-specific prevalence. PloS one 9 (6):e99857. doi:10.1371/journal.pone.0099857 
4. zur Hausen H, Schulte-Holthausen H, Klein G, Henle W, Henle G, Clifford P, Santesson L 
(1970) EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the 
nasopharynx. Nature 228 (5276):1056-1058 
5. Correa P, Piazuelo MB, Camargo MC (2004) The future of gastric cancer prevention. 
Gastric Cancer 7 (1):9-16. doi:10.1007/s10120-003-0265-0 
6. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, 
Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates 
for 40 countries in 2012. Eur J Cancer 49 (6):1374-1403. 
doi:10.1016/j.ejca.2012.12.027 
7. BenAyed-Guerfali D, Ayadi W, Miladi-Abdennadher I, Khabir A, Sellami-Boudawara T, 
Gargouri A, Mokdad-Gargouri R (2011) Characteristics of epstein barr virus variants 
associated with gastric carcinoma in Southern Tunisia. Virology journal 8:500. 
doi:10.1186/1743-422x-8-500 
8. Camargo MC, Murphy G, Koriyama C, Pfeiffer RM, Kim WH, Herrera-Goepfert R, 
Corvalan AH, Carrascal E, Abdirad A, Anwar M, Hao Z, Kattoor J, Yoshiwara-
Wakabayashi E, Eizuru Y, Rabkin CS, Akiba S (2011) Determinants of Epstein-Barr 
virus-positive gastric cancer: an international pooled analysis. British journal of cancer 
105 (1):38-43. doi:10.1038/bjc.2011.215 
9. Cancer Genome Atlas Research N (2014) Comprehensive molecular characterization of 
gastric adenocarcinoma. Nature 513 (7517):202-209. doi:10.1038/nature13480 
10. Akiba S, Koriyama C, Herrera-Goepfert R, Eizuru Y (2008) Epstein-Barr virus associated 
gastric carcinoma: epidemiological and clinicopathological features. Cancer science 99 
(2):195-201. doi:10.1111/j.1349-7006.2007.00674.x 
11. Sousa H, Pinto-Correia AL, Medeiros R, Dinis-Ribeiro M (2008) Epstein-Barr virus is 
associated with gastric carcinoma: the question is what is the significance? World 
journal of gastroenterology 14 (27):4347-4351 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
12. Zong L, Seto Y (2014) CpG island methylator phenotype, Helicobacter pylori, Epstein-
Barr virus, and microsatellite instability and prognosis in gastric cancer: a systematic 
review and meta-analysis. PloS one 9 (1):e86097. doi:10.1371/journal.pone.0086097 
13. Herath CH, Chetty R (2008) Epstein-Barr virus-associated lymphoepithelioma-like gastric 
carcinoma. Archives of pathology & laboratory medicine 132 (4):706-709. 
doi:10.1043/1543-2165(2008)132[706:EVLGC]2.0.CO;2 
14. Shibata D, Weiss LM (1992) Epstein-Barr virus-associated gastric adenocarcinoma. The 
American journal of pathology 140 (4):769-774 
15. Imai S, Koizumi S, Sugiura M, Tokunaga M, Uemura Y, Yamamoto N, Tanaka S, Sato E, 
Osato T (1994) Gastric carcinoma: monoclonal epithelial malignant cells expressing 
Epstein-Barr virus latent infection protein. Proceedings of the National Academy of 
Sciences of the United States of America 91 (19):9131-9135 
16. Levine PH, Stemmermann G, Lennette ET, Hildesheim A, Shibata D, Nomura A (1995) 
Elevated antibody titers to Epstein-Barr virus prior to the diagnosis of Epstein-Barr-
virus-associated gastric adenocarcinoma. International journal of cancer Journal 
international du cancer 60 (5):642-644 
17. Zhao J, Liang Q, Cheung KF, Kang W, Lung RW, Tong JH, To KF, Sung JJ, Yu J (2013) 
Genome-wide identification of Epstein-Barr virus-driven promoter methylation profiles 
of human genes in gastric cancer cells. Cancer 119 (2):304-312. 
doi:10.1002/cncr.27724 
18. Wang K, Yuen ST, Xu J, Lee SP, Yan HH, Shi ST, Siu HC, Deng S, Chu KM, Law S, 
Chan KH, Chan AS, Tsui WY, Ho SL, Chan AK, Man JL, Foglizzo V, Ng MK, Chan AS, 
Ching YP, Cheng GH, Xie T, Fernandez J, Li VS, Clevers H, Rejto PA, Mao M, Leung 
SY (2014) Whole-genome sequencing and comprehensive molecular profiling identify 
new driver mutations in gastric cancer. Nature genetics 46 (6):573-582. 
doi:10.1038/ng.2983 
19. Chen X, Kamranvar SA, Masucci MG (2015) Oxidative stress enables Epstein-Barr 
virus-induced B-cell transformation by posttranscriptional regulation of viral and cellular 
growth-promoting factors. Oncogene. doi:10.1038/onc.2015.450 
20. Tempera I, De Leo A, Kossenkov AV, Cesaroni M, Song H, Dawany N, Showe L, Lu F, 
Wikramasinghe P, Lieberman PM (2015) Identification of MEF2B, EBF1, and IL6R as 
Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-
Infected B-Lymphocyte Survival. Journal of virology 90 (1):345-355. 
doi:10.1128/JVI.02318-15 
21. Young LS, Dawson CW, Eliopoulos AG (2000) The expression and function of Epstein-
Barr virus encoded latent genes. Molecular pathology : MP 53 (5):238-247 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
22. Tanyildiz HG, Yildiz I, Bassullu N, Tuzuner N, Ozkan A, Celkan T, Apak H (2015) The 
Role of Epstein-Barr Virus LMP-1 Immunohistochemical Staining in Childhood Hodgkin 
Lymphoma. Iranian journal of pediatrics 25 (6):e2359. doi:10.5812/ijp.2359 
23. zur Hausen A, Brink AA, Craanen ME, Middeldorp JM, Meijer CJ, van den Brule AJ 
(2000) Unique transcription pattern of Epstein-Barr virus (EBV) in EBV-carrying gastric 
adenocarcinomas: expression of the transforming BARF1 gene. Cancer research 60 
(10):2745-2748 
24. Chen JN, Jiang Y, Li HG, Ding YG, Fan XJ, Xiao L, Han J, Du H, Shao CK (2011) 
Epstein-Barr virus genome polymorphisms of Epstein-Barr virus-associated gastric 
carcinoma in gastric remnant carcinoma in Guangzhou, southern China, an endemic 
area of nasopharyngeal carcinoma. Virus research 160 (1-2):191-199. 
doi:10.1016/j.virusres.2011.06.011 
25. Tang W, Morgan DR, Meyers MO, Dominguez RL, Martinez E, Kakudo K, Kuan PF, 
Banet N, Muallem H, Woodward K, Speck O, Gulley ML (2012) Epstein-barr virus 
infected gastric adenocarcinoma expresses latent and lytic viral transcripts and has a 
distinct human gene expression profile. Infectious agents and cancer 7 (1):21. 
doi:10.1186/1750-9378-7-21 
26. Rowlands DC, Ito M, Mangham DC, Reynolds G, Herbst H, Hallissey MT, Fielding JW, 
Newbold KM, Jones EL, Young LS, et al. (1993) Epstein-Barr virus and carcinomas: 
rare association of the virus with gastric adenocarcinomas. British journal of cancer 68 
(5):1014-1019 
27. Takano Y, Kato Y, Sugano H (1994) Epstein-Barr-virus-associated medullary 
carcinomas with lymphoid infiltration of the stomach. Journal of cancer research and 
clinical oncology 120 (5):303-308 
28. Gulley ML, Pulitzer DR, Eagan PA, Schneider BG (1996) Epstein-Barr virus infection is 
an early event in gastric carcinogenesis and is independent of bcl-2 expression and 
p53 accumulation. Human pathology 27 (1):20-27 
29. Selves J, Bibeau F, Brousset P, Meggetto F, Mazerolles C, Voigt JJ, Pradere B, 
Chiotasso P, Delsol G (1996) Epstein-Barr virus latent and replicative gene expression 
in gastric carcinoma. Histopathology 28 (2):121-127 
30. Sugita M, Sugiura M (1996) Regulation of gene expression in chloroplasts of higher 
plants. Plant molecular biology 32 (1-2):315-326 
31. Sugiura M, Imai S, Tokunaga M, Koizumi S, Uchizawa M, Okamoto K, Osato T (1996) 
Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric 
carcinoma: unique viral latency in the tumour cells. British journal of cancer 74 (4):625-
631 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
32. Hoshikawa Y, Satoh Y, Murakami M, Maeta M, Kaibara N, Ito H, Kurata T, Sairenji T 
(2002) Evidence of lytic infection of Epstein-Barr virus (EBV) in EBV-positive gastric 
carcinoma. Journal of medical virology 66 (3):351-359 
33. Lee MA, Hong YS, Kang JH, Lee KS, You JY, Lee KY, Park CH (2004) Detection of 
Epstein-Barr virus by PCR and expression of LMP1, p53, CD44 in gastric cancer. The 
Korean journal of internal medicine 19 (1):43-47 
34. Luo B, Wang Y, Wang XF, Liang H, Yan LP, Huang BH, Zhao P (2005) Expression of 
Epstein-Barr virus genes in EBV-associated gastric carcinomas. World journal of 
gastroenterology 11 (5):629-633 
35. Seto E, Yang L, Middeldorp J, Sheen TS, Chen JY, Fukayama M, Eizuru Y, Ooka T, 
Takada K (2005) Epstein-Barr virus (EBV)-encoded BARF1 gene is expressed in 
nasopharyngeal carcinoma and EBV-associated gastric carcinoma tissues in the 
absence of lytic gene expression. J Med Virol 76 (1):82-88. doi:10.1002/jmv.20327 
36. Wang Y, Luo B, Yan LP, Huang BH, Zhao P (2005) Relationship between Epstein-Barr 
virus-encoded proteins with cell proliferation, apoptosis, and apoptosis-related proteins 
in gastric carcinoma. World journal of gastroenterology 11 (21):3234-3239 
37. Kim do N, Chae HS, Oh ST, Kang JH, Park CH, Park WS, Takada K, Lee JM, Lee WK, 
Lee SK (2007) Expression of viral microRNAs in Epstein-Barr virus-associated gastric 
carcinoma. Journal of virology 81 (2):1033-1036. doi:10.1128/JVI.02271-06 
38. Ryan JL, Morgan DR, Dominguez RL, Thorne LB, Elmore SH, Mino-Kenudson M, 
Lauwers GY, Booker JK, Gulley ML (2009) High levels of Epstein-Barr virus DNA in 
latently infected gastric adenocarcinoma. Lab Invest 89 (1):80-90. 
doi:10.1038/labinvest.2008.103 
39. Chen JN, Ding YG, Feng ZY, Li HG, He D, Du H, Wu B, Shao CK (2010) Association of 
distinctive Epstein-Barr virus variants with gastric carcinoma in Guangzhou, southern 
China. Journal of medical virology 82 (4):658-667. doi:10.1002/jmv.21731 
40. Lee JM, Kim H, Noh SH, Lee WY, Kim SJ, Park JH (2011) Expression of Epstein-Barr 
Virus Gene and Clonality of Infiltrated T Lymphocytes in Epstein-Barr Virus-associated 
Gastric Carcinoma. Immune network 11 (1):50-58. doi:10.4110/in.2011.11.1.50 
41. Han J, Chen JN, Zhang ZG, Li HG, Ding YG, Du H, Shao CK (2012) Sequence 
variations of latent membrane protein 2A in Epstein-Barr virus-associated gastric 
carcinomas from Guangzhou, southern China. PloS one 7 (3):e34276. 
doi:10.1371/journal.pone.0034276 
42. Shukla SK, Prasad KN, Tripathi A, Ghoshal UC, Krishnani N, Husain N (2012) 
Expression profile of latent and lytic transcripts of epstein-barr virus in patients with 
gastroduodenal diseases: a study from northern India. Journal of medical virology 84 
(8):1289-1297. doi:10.1002/jmv.23322 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
43. Strong MJ, Xu G, Coco J, Baribault C, Vinay DS, Lacey MR, Strong AL, Lehman TA, 
Seddon MB, Lin Z, Concha M, Baddoo M, Ferris M, Swan KF, Sullivan DE, Burow ME, 
Taylor CM, Flemington EK (2013) Differences in gastric carcinoma microenvironment 
stratify according to EBV infection intensity: implications for possible immune adjuvant 
therapy. PLoS pathogens 9 (5):e1003341. doi:10.1371/journal.ppat.1003341 
44. Zhu S, Sun P, Zhang Y, Yan L, Luo B (2013) Expression of c-myc and PCNA in Epstein-
Barr virus-associated gastric carcinoma. Experimental and therapeutic medicine 5 
(4):1030-1034. doi:10.3892/etm.2013.972 
45. Cheng N, Hui DY, Liu Y, Zhang NN, Jiang Y, Han J, Li HG, Ding YG, Du H, Chen JN, 
Shao CK (2015) Is gastric lymphoepithelioma-like carcinoma a special subtype of 
EBV-associated gastric carcinoma? New insight based on clinicopathological features 
and EBV genome polymorphisms. Gastric cancer : official journal of the International 
Gastric Cancer Association and the Japanese Gastric Cancer Association 18 (2):246-
255. doi:10.1007/s10120-014-0376-9 
46. Shinozaki-Ushiku A, Kunita A, Isogai M, Hibiya T, Ushiku T, Takada K, Fukayama M 
(2015) Profiling of Virus-Encoded MicroRNAs in Epstein-Barr Virus-Associated Gastric 
Carcinoma and Their Roles in Gastric Carcinogenesis. Journal of virology 89 
(10):5581-5591. doi:10.1128/JVI.03639-14 
47. Zhang YW, Zhao XX, Tan C, Zhang ZG, Jiang Y, Chen JN, Wei HB, Xue L, Li HG, Du H, 
Shao CK (2015) Epstein-Barr virus latent membrane protein 2A suppresses the 
expression of HER2 via a pathway involving TWIST and YB-1 in Epstein-Barr virus-
associated gastric carcinomas. Oncotarget 6 (1):207-220. 
doi:10.18632/oncotarget.2702 
48. Young LS, Murray PG (2003) Epstein-Barr virus and oncogenesis: from latent genes to 
tumours. Oncogene 22 (33):5108-5121. doi:10.1038/sj.onc.1206556 
49. Yoshioka M, Kikuta H, Ishiguro N, Ma X, Kobayashi K (2003) Unique Epstein-Barr virus 
(EBV) latent gene expression, EBNA promoter usage and EBNA promoter methylation 
status in chronic active EBV infection. The Journal of general virology 84 (Pt 5):1133-
1140. doi:10.1099/vir.0.18777-0 
50. Day L, Chau CM, Nebozhyn M, Rennekamp AJ, Showe M, Lieberman PM (2007) 
Chromatin profiling of Epstein-Barr virus latency control region. Journal of virology 81 
(12):6389-6401. doi:10.1128/JVI.02172-06 
51. Dawson CW, Port RJ, Young LS (2012) The role of the EBV-encoded latent membrane 
proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC). 
Seminars in cancer biology 22 (2):144-153. doi:10.1016/j.semcancer.2012.01.004 
52. Yang CF, Yang GD, Huang TJ, Li R, Chu QQ, Xu L, Wang MS, Cai MD, Zhong L, Wei 
HJ, Huang HB, Huang JL, Qian CN, Huang BJ (2015) EB-virus latent membrane 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
protein 1 potentiates the stemness of nasopharyngeal carcinoma via preferential 
activation of PI3K/AKT pathway by a positive feedback loop. Oncogene. 
doi:10.1038/onc.2015.402 
53. Morris MA, Dawson CW, Laverick L, Davis AM, Dudman JP, Raveenthiraraj S, Ahmad Z, 
Yap LF, Young LS (2016) The Epstein-Barr virus encoded LMP1 oncoprotein 
modulates cell adhesion via regulation of activin A/TGFbeta and beta1 integrin 
signalling. Scientific reports 6:19533. doi:10.1038/srep19533 
54. Lee JH, Kim SH, Han SH, An JS, Lee ES, Kim YS (2009) Clinicopathological and 
molecular characteristics of Epstein-Barr virus-associated gastric carcinoma: a meta-
analysis. Journal of gastroenterology and hepatology 24 (3):354-365. 
doi:10.1111/j.1440-1746.2009.05775.x 
55. Kida Y, Miyauchi K, Takano Y (1993) Gastric adenocarcinoma with differentiation to 
sarcomatous components associated with monoclonal Epstein-Barr virus infection and 
LMP-1 expression. Virchows Archiv A, Pathological anatomy and histopathology 423 
(5):383-387 
56. Ambinder RF, Mann RB (1994) Epstein-Barr-encoded RNA in situ hybridization: 
diagnostic applications. Human pathology 25 (6):602-605 
57. Lauren P (1965) The Two Histological Main Types of Gastric Carcinoma: Diffuse and So-
Called Intestinal-Type Carcinoma. An Attempt at a Histo-Clinical Classification. Acta 
pathologica et microbiologica Scandinavica 64:31-49 
58. Shibata D, Tokunaga M, Uemura Y, Sato E, Tanaka S, Weiss LM (1991) Association of 
Epstein-Barr virus with undifferentiated gastric carcinomas with intense lymphoid 
infiltration. Lymphoepithelioma-like carcinoma. The American journal of pathology 139 
(3):469-474 
59. Chen YL, Liu CD, Cheng CP, Zhao B, Hsu HJ, Shen CL, Chiu SJ, Kieff E, Peng CW 
(2014) Nucleolin is important for Epstein-Barr virus nuclear antigen 1-mediated 
episome binding, maintenance, and transcription. Proceedings of the National 
Academy of Sciences of the United States of America 111 (1):243-248. 
doi:10.1073/pnas.1321800111 
60. Yates J, Warren N, Reisman D, Sugden B (1984) A cis-acting element from the Epstein-
Barr viral genome that permits stable replication of recombinant plasmids in latently 
infected cells. Proceedings of the National Academy of Sciences of the United States 
of America 81 (12):3806-3810 
61. Frappier L (2015) Ebna1. Current topics in microbiology and immunology 391:3-34. 
doi:10.1007/978-3-319-22834-1_1 
62. Lin YC, Benner C, Mansson R, Heinz S, Miyazaki K, Miyazaki M, Chandra V, Bossen C, 
Glass CK, Murre C (2012) Global changes in the nuclear positioning of genes and 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
intra- and interdomain genomic interactions that orchestrate B cell fate. Nature 
immunology 13 (12):1196-1204. doi:10.1038/ni.2432 
63. Li J, Liu X, Liu M, Che K, Luo B (2016) Methylation and expression of Epstein-Barr virus 
latent membrane protein 1, 2A and 2B in EBV-associated gastric carcinomas and cell 
lines. Digestive and liver disease : official journal of the Italian Society of 
Gastroenterology and the Italian Association for the Study of the Liver 48 (6):673-680. 
doi:10.1016/j.dld.2016.02.017 
64. Hino R, Uozaki H, Murakami N, Ushiku T, Shinozaki A, Ishikawa S, Morikawa T, Nakaya 
T, Sakatani T, Takada K, Fukayama M (2009) Activation of DNA methyltransferase 1 
by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN 
gene in gastric carcinoma. Cancer research 69 (7):2766-2774. doi:10.1158/0008-
5472.CAN-08-3070 
65. Jiang R, Cabras G, Sheng W, Zeng Y, Ooka T (2009) Synergism of BARF1 with Ras 
induces malignant transformation in primary primate epithelial cells and human 
nasopharyngeal epithelial cells. Neoplasia 11 (9):964-973 
66. Chang MS, Kim DH, Roh JK, Middeldorp JM, Kim YS, Kim S, Han S, Kim CW, Lee BL, 
Kim WH, Woo JH (2013) Epstein-Barr virus-encoded BARF1 promotes proliferation of 
gastric carcinoma cells through regulation of NF-kappaB. Journal of virology 87 
(19):10515-10523. doi:10.1128/JVI.00955-13 
67. Hsu JL, Glaser SL (2000) Epstein-barr virus-associated malignancies: epidemiologic 
patterns and etiologic implications. Critical reviews in oncology/hematology 34 (1):27-
53 
68. Iizasa H, Nanbo A, Nishikawa J, Jinushi M, Yoshiyama H (2012) Epstein-Barr Virus 
(EBV)-associated gastric carcinoma. Viruses 4 (12):3420-3439 
69. Shinozaki-Ushiku A, Kunita A, Fukayama M (2015) Update on Epstein-Barr virus and 
gastric cancer (review). International journal of oncology 46 (4):1421-1434. 
doi:10.3892/ijo.2015.2856 
 
 
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
PRISMA 2009 Flow Diagram 
Records identified through 
database searching 
(n =247) 
S
cr
e
e
n
in
g
 
In
cl
u
d
e
d
 
E
li
g
ib
il
it
y
 
Id
e
n
ti
fi
ca
ti
o
n
 
Additional records identified 
through other sources 
(n =0) 
Records after duplicates removed 
(n =0) 
Records screened 
(n =247) 
Full-text articles assessed 
for eligibility 
(n =57) 
Full-text articles excluded (n =32) 
· Do not evaluate the expression 
of EBV proteins (n=15) 
· In vitro studies (n=3) 
· Articles in Chinese (n=4) 
· Case report (n=1) 
· No access to full-text (n=5) 
· Replicated data (n=3) 
· MALT lymphoma (n=1)  
Studies included in 
qualitative synthesis 
(n = 25) 
Records excluded (n =190) 
· Do not evaluate the expression 
of EBV proteins (n=39) 
· In vitro studies (n=55) 
· Not related with gastric cancer 
(n=40) 
· Review (n=56) 
)LJXUH
Table I: Baseline characteristics of included studies.
 
STUDY Population
Type of 
Sample 
Histological information
EBV+
(n)
Methodology 
of EBV 
detection 
Latent proteins analysed
(method of analysis)
Others genes analysed
(method of analysis)
Shinozaki-Ushiku A. et al. 
2015 [29] 
Japan FFPE ND 10 EBER-ISH  BHRF1, BARTs (RT-PCR) 
Cheng N. et al. 2015 [30] China  FFPE LELCs  8 EBER-ISH 
EBNA1, EBNA2, LMP1, 
LMP2A (IHC) 
BZLF1 (IHC) 
Zhang YW. et al. 2015 [31] China FFPE 
Adenocarcinomas:  
Diffuse type (n=60) 
Intestinal type (n=18)  
78 EBER-ISH LMP2A (IHC)   
Zhu S. et al.2013 [32] China Tissue ND 13 RT-PCR* 
EBNA1, EBNA2, LMP1 (RT-
PCR*)  
BARF1, BHRF1 (RT-PCR*)  
Strong M. et al. 2013 [33]33] ND Tissue ND 4 RNA compass 
EBNA1, EBNA2, LMP1, 
LMP2A, LMP2B (RNA 
compass)  
BRLF, BARF0, BZLF1 
(RNA compass) 
Shukla SK. et al. 2012 [34] India  
Frozen 
tissue  
Adenocarcinomas: 
Diffuse type (n=22),  
Intestinal type (n=18)  
40 
EBNA1-RT-
PCR 
EBNA1 (RT-PCR) 
BARF1, BZLF1, BCLF1 
(RT-PCR)  
Tang W. et al. 2012 [25] 
USA, Central 
America and 
Japan 
FFPE 
Adenocarcinomas not 
classified  
14 EBER-ISH 
EBNA1, EBNA2, EBNA3C, 
EBNA-LP, LMP1, LMP2A 
(array) 
BARF1, BZLF1, BMRF1, 
BHRF1, BCRF1, BRLF1, 
BLLF1, BALF5, BXLF1 
(array) 
Han J. et al. 2012 [35] China FFPE 
Adenocarcinomas: 
Diffuse type (n=45),  
Intestinal type (n=8) 
53 EBER-ISH LMP2A (IHC)   
Lee J M. et al. 2011 [36] Korea FFPE 
Undifferentiated 
Adenocarcinomas (n=2) 
LELCs (n=2) 
4 EBER-ISH 
EBNA1, EBNA2, LMP1, 
LMP2A (RT-PCR) 
BARTs (RT-PCR)  
Chen J. et al. 2011 [23] China FFPE 
Adenocarcinomas:  
Diffuse type (n=8) 
8 EBER-ISH 
EBNA1, EBNA2, LMP1, 
LMP2A (IHC) 
BZLF1 (IHC) 
Chen J. et al. 2010 [37] China FFPE 
Adenocarcinomas:  
Diffuse type (n=37)  
Intestinal type (n=18)  
45 EBER-ISH EBNA1, EBNA2, LMP1 (IHC) BZLF1 (IHC) 
Ryan J. et al. 2009 [38] 
USA and 
Central 
America  
FFPE 
Adenocarcinomas:  
Diffuse type (n=6),  
Intestinal type (n=5),  
11 EBER-ISH LMP1, LMP2A (IHC) BMRF1, BZLF1 (IHC) 
7DEOH,
Mixed type (n=1) 
Kim D. et al. 2007 [39] Japan FFPE ND 4 EBER-ISH  
BARTs, BHRF1 (Northern 
blot)  
Luo B. et al. 2005 [40] China  FFPE ND 11 EBER-ISH 
EBNA1, EBNA2, LMP1, 
LMP2A, LMP2B (RT-PCR*) 
BZLF1, BRLF1, BARF1, 
BHRF1, BcLF1, BLLF1 (RT-
PCR*)  
Wang Y. et al. 2005 [41] China FFPE 
Adenocarcinomas (n=12) 
Signet ring carcinoma  (n=1) 
13 EBER-ISH 
EBNA 1, EBNA2, LMP1 (RT-
PCR*)  
BARF1, BHRF1, BZLF1 
(RT-PCR*)  
Seto E. et al. 2005 [42] Japan 
Tumor 
biopsies 
ND 6 EBER-ISH EBNA1 (RT-qPCR)  BARF1, BZLF1 (RT-qPCR)  
Lee M. et al. 2004 [43] Korea FFPE 
Adenocarcinomas: 
Diffuse type (n=1),  
Intestinal type (n=2) 
 Mixed type (n=1) 
4 EBNA1 (PCR) LMP1 (IHC)   
Hoshikawa Y. et al. 2002 
[44] 
Japan FFPE 
Adenocarcinomas not 
classified 
3 EBER-ISH 
EBNA1, EBNA2, LMP1, 
LMP2A (RT-PCR) 
BZLF1, BRLF1, BcLF1, 
BLLF1 (RT-PCR)  
zur Hausen A. et al. 2000 
[24] 
Netherlands  FFPE 
Adenocarcinomas not 
classified 
10 EBER-ISH 
EBNA1, LMP1 (RT-PCR and 
IHC) EBNA2, LMP2A (RT-
PCR)  
BARF1 (NASBA) BARF0, 
BHFR1 (RT-PCR) BZLF1 
(RT-PCR and IHC) 
Sugiura M et al. 1996 [27] Japan  
Frozen 
tissue  
LELC (n=1) 
Well differentiated (n=1) 
Poorly differentiated (n=2) 
Moderated differentiated  (n=3) 
7 EBER-ISH 
EBNA1, EBNA2, LMP1, 
LMP2A, LMP2B (RT-PCR*) 
BZLF1 (IFA) 
Selves J. et al. 1996 [46] France FFPE 
LELCs (n=4), 
Well differentiated (n=1) 
5 EBER-ISH LMP1 (IHC)  BHRF1 (ISH)  
Gulley M et al. 1996 [47] USA FFPE 
Adenocarcinomas:  
Diffuse type (n=7) 
Intestinal type (n=4), 
11 EBER-ISH LMP1 (IHC)   
Imai S. et al. 1994 [15] Japan 
FFPE 
and 
Frozen 
ULCs (n=8),  
Adenocarcinomas: poorly 
differentiated (n=27) 
mod. to well-differentiated 
(n=35) 
20 EBER-ISH 
EBNA1(western-blot and IF) 
EBNA2, LMP1 (western-blot) 
 
Takano Y et al. 1994 [26] Japan FFPE 
Medullary carcinomas with 
lymphoid infiltration (n=27) 
27 EBER-ISH LMP1 (IHC)   
Rowlands D. et al. 1993 [28] UK and Japan FFPE 
UCNT (n=6) 
Intestinal type (n=1) 
Mixed type (n=2) 
9 EBER-ISH EBNA2, LMP1 (IHC)  BZLF1 (IHC)  
Table II: Expression of EBV latent proteins  
Study n
EBNA1
n (%)
EBNA2
n (%)
LMP1
n (%)
LMP2A
n (%)
LMP2B
n (%)
Cheng N, et al. 2015 [30] 7 7 (100) 0 (0) 0 (0) 5 (71.4) ---- 
Zang YW, et al. 2015 [31] 78 ---- ---- ---- 37 (47.4) ---- 
Zhu S, et al. 2013 [32] 13 13 (100) 0 (0) 0 (0) ---- ---- 
Strong M, et al. 2013 [33] 4 3 (75.0) 0 (0) 3 (75.0) * 3 (75.0) 3 (75.0) 
Han J, et al. 2012 [35] 53 ---- ---- ---- 29 (54.7) ---- 
Tang W, et al. 2012 [25] 14 14 100) 6 (42.9) * 14 (100) 14 (100) ---- 
Shukla SK, et al. 2012 [34] 40 40 (100) ---- ---- ---- ---- 
Lee JM. et al. 2011 [36] 4 4 (100) 0 (0) 0 (0) 1 (25.0) ---- 
Chen J. et al. 2011 [23] 8 7 (87.5) 0 (0) 0 (0) 5 (62.5) ---- 
Chen J et al. 2010 [37] 45 42 (93.3) 0 (0) 0 (0) ---- ---- 
Ryan J. et al. 2007 [39] 11 ---- ---- 1 (9.0) 4 (36.4) ---- 
Seto E, et al. 2005 [42] 6 6 (100) ---- ---- ---- ---- 
Wang Y, et al. 2005 [41] 13 13 (100) 0 (0) 0 (0) ---- ---- 
Luo B, et al. 2005 [40] 11 11  (100) 0 (0) 0 (0) 4 (36.4) 0 (0) 
Lee M, te al. 2004 [43] 4 4 (100) ---- 0 (0) ---- ---- 
Hoshikawa Y, et al. 2002 [44] 3 3 (100) 0 (0) 0 (0) 2 (66.7) ---- 
zur Hausen A, et al. 2000 [24] 10 10 (100) 0 (0) 0 (0) 6 (60.0) ---- 
Gulley M, et al. 1996 [47] 11 ---- ---- 3 (27.3) ---- ---- 
Selves J, et al. 1996  5 ---- ---- 0 (0) ---- ---- 
Sugiura M, et al. 1996 [27] 7 7 (100) 0 (0) 0 (0) 3 (42.9) 0 (0) 
Imai S, et al. 1994 [15]  70/70 (100) 0/20 (0) 0/20 (0) ---- ---- 
Takano Y, et al. 1994 [26] 27 ---- 0 (0) ---- ---- ---- 
Rowlands D, et al. 1993 [28]  ---- 0/7 (0) 0/9 (0) ---- ---- 
TOTAL  
254/259 
(98.1) 
6/193 (3.1) 21/199 (10.6) 
113/210 
(53.8) 
3/22 (13.6) 
* Low albeit detectable level
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Table III: Expression of EBV lytic genes 
Study N
BARF0
n (%)
BARF1
n (%) 
BHRF1
n (%)
BARTs
n (%)
BLLF1
n (%)
BMRF1
n (%)
BcLF1
n (%)
BRLF1
n (%)
BZLF1
n (%)
Cheng N, et al. 2015 [30] 8 ---- ---- ---- ---- ---- ---- ---- ---- 0 (0) 
Zhu S, et al. 2013 [32] 13 --- 8 (46.2) 2 (15.4) --- --- --- --- --- ---- 
Strong M, et al. 2013 [33] 4 4 (100) ---- ---- ---- ---- ---- ---- 3 (75.0) 3 (75.0) 
Tang W, et al. 2012* [25] 14 ---- 14 (100) ---- ---- 13 (92.9) 12 (85.7) ---- 14 (100) 13 (92.9) 
Shukla SK, et al. 2012 [34] 40 ---- 30 (75.0) ---- 25 (62.5) 25 (62.5) ---- 25 (62.5) ---- 31 (77.5) 
Lee JM. et al. 2011  [36] 4 ---- ---- ---- 0 (0) 0 (0) ---- ---- ---- ---- 
Chen J. et al. 2011 [23] 4 ---- ---- ---- ---- ---- ---- ---- ---- 0 (0) 
Chen J, et al. 2010 [37] 45 ---- ---- ---- ---- ---- ---- ---- ---- 0 (0) 
Kim D. et al. 2007 [39] 4 ---- ---- 0 (0) 4 (100) 4 (100) ---- ---- ---- ---- 
Ryan J. et al. 2009 [38] 11 ---- ---- ---- ---- ---- 0 (0) ---- ---- 0 (0) 
Seto E, et al. 2005 [42] 6 ---- 5 (83.3) ---- ---- ---- ---- ---- ---- 0 (0) 
Wang Y, et al. 2005 [41] 13 ---- 6 (46.2) 2 (15.4) ---- ---- ---- ---- ---- 6 (46.2) 
Luo B, et al. 2005 [40] 11 ---- 5 (45.5) 2 (18.2) ---- 0 (0) ---- 7 (63.6) 0 (0) 5 (45.5) 
Hoshikawa Y, et al. 2002 [44] 3 ---- ---- ---- ---- 3 (100)  1 (33.3) 1 (33.3) 2 (66.7) 
zur Hausen A, et al. 2000 [24] 10 10 (100) 10 (100) 2 (20.0) ---- ---- ---- ---- ---- 0 (0) 
Selves J, et al. 1996 [46] 5 ---- ---- 1 (20.0) ---- ---- ---- ---- ---- ---- 
Sugiura M, et al. 1996 [27] 7 ---- ---- ---- ---- ---- ---- ---- ---- 0 (0) 
Rowlands D, et al. 1993 [28] 8 ---- ---- ---- ---- ---- ---- ---- ---- 3 (37.5) 
TOTAL  
14/14 
(100) 
78/122 
(63.9) 
9/56 (8.02) 
29/48 
(60.4) 
45/76 
(59.2) 
12/25 
(48.0) 
33/54 
(61.1) 
18/32 
(56.2) 
63/184 
(34.2) 
* Tang W, et al. also observed the expression of BALF5 and BXLF1in all cases and BCRF1 in 11 of 14 cases.  
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Table IV  Description of latency patterns  
 
1The classification of these cases into latency I is based on the presence of both EBNA1 and LMP2A 
and absence of EBNA2 and LMP1. Authors also showed that BARF1 is present in all tested cases so 
this is not a typical latency I pattern. 
 
Author, Year
Latency I
n
Latency II
n
Latency III
n
Latency II-like
n
Cheng N, et al. 2015 [30] 2/7 ---- ---- 5/7
Tang W, et al. 2012 [25] ---- 8/14 6/14 ----
Chen J, et al.2011 [23] 2/7 ---- ---- 5/7
Lee J M, 2011 [36] 3/4 ---- ---- 1/4
Luo B, et al, 2005 [40] 7/11 ---- ---- 4/11
Hoshikawa Y, et al, 2002 [44] 1/4 ---- ---- 3/4
zur Hausen A, 2000 [24] 
2/9 1
---- ---- 7/9
Sugiura M, 1996 [27] 4/7 ---- ---- 3/7
7DEOH,9
